Methods of treating cancer with alkyne-substituted quinazoline derivatives

JP2023548055A5Pending Publication Date: 2024-11-13BLACK DIAMOND THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023524708
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-09-15
Filing Date
2021-11-02
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Current ErbB inhibitors are ineffective for treating cancers with oncogenic variants of the ErbB receptor, such as EGFR-Viii, due to paradoxical activation at subsaturating concentrations and heterogeneous genotypic expression patterns, leading to variable patient responsiveness.

Method used

Development of alkyne-substituted quinazoline derivatives that inhibit oncogenic variants of the ErbB receptor, including EGFR-Viii, by targeting the extracellular ligand-binding domain, thereby preventing covalent dimerization and constitutive activation.

Benefits of technology

The alkyne-substituted quinazoline derivatives effectively inhibit oncogenic variants of the ErbB receptor, reducing tumor growth and improving treatment outcomes in cancers like glioblastoma and non-small cell lung cancer, overcoming the limitations of existing ErbB inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure relates to methods for treating or preventing cancer (e.g., advanced solid cancers) using Compound 1 or Compound 2, or a pharmaceutically acceptable salt thereof. The present disclosure also relates to pharmaceutical compositions and pharmaceutical kits suitable for the treatment or prevention. JPEG2023548055000020.jpg93142
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 244,540, filed September 15, 2021, U.S. Provisional Patent Application No. 63 / 237,782, filed August 27, 2021, U.S. Provisional Patent Application No. 63 / 218,717, filed July 6, 2021, U.S. Provisional Patent Application No. 63 / 190,067, filed May 18, 2021, U.S. Provisional Patent Application No. 63 / 166,045, filed March 25, 2021, and U.S. Provisional Patent Application No. 63 / 108,645, filed November 2, 2020, the entire contents of each of which are incorporated herein by reference.

[0002] Sequence Listing This application contains a Sequence Listing that has been submitted in ASCII format via EFS-Web, which is incorporated herein by reference in its entirety. The ASCII copy, created on November 2, 2021, is named "ASET-023_001WO_SeqList.txt" and is approximately 57,901 bytes in size. [Background technology]

[0003] Mutations affecting either the intracellular catalytic domain or the extracellular ligand-binding domain of ErbB receptors can result in oncogenic activity. (The ErbB protein family consists of four members, including ErbB-1, also known as epidermal growth factor receptor (EGFR), and Erb-2, also known as HER2, in humans.) ErbB inhibitors are known treatments for some cancers. However, not all patients respond adequately to this treatment. Thus, there is a long-felt need in the art for new therapies that can address the variable responsiveness of cancer patients to known therapies. The present disclosure provides compositions and methods for preventing or treating cancer in patients with these oncogenic mutations without the variable responsiveness observed when patients with these ErbB variants are treated using existing standard therapies. Summary of the Invention

[0004] In some aspects, the present disclosure provides a method of treating or preventing cancer in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of Compound 1, or a pharmaceutically acceptable salt thereof.

[0005] In some aspects, the present disclosure provides Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof for treating or preventing cancer in a subject in need thereof.

[0006] In some aspects, the present disclosure provides the use of Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing cancer in a subject in need thereof.

[0007] In some aspects, the present disclosure provides a pharmaceutical composition for treating or preventing cancer, comprising Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof.

[0008] In some aspects, the present disclosure provides a pharmaceutical kit for treating or preventing cancer, comprising Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof.

[0009] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. As used herein, the singular also includes the plural unless the context clearly indicates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference. References cited herein are not admitted to be prior art to the claimed invention. In case of conflict, the present specification, including definitions, will control. Furthermore, the materials, methods, and examples are illustrative only and not intended to be limiting. In the event of a conflict between a chemical structure and the name of a compound disclosed herein, the chemical structure controls.

[0010] Features and advantages of the present disclosure will become apparent from the following detailed description and claims. [Brief explanation of the drawings]

[0011] [Figure 1] FIG. 1 is a graph showing the anti-proliferative IC50 values of compound 1A in EGFR-WT, EGFR-Viii, EGFR-Vii, EGFR-Vvi, EGFR-A289V, and EGFR-G598V.

[0012] [Figure 2] FIG. 2 is a graph showing the mean plasma and brain concentrations of Compound 1A (15 mg / kg), where the black bars represent plasma concentrations and the gray bars represent brain concentrations.

[0013] [Figure 3] FIG. 3 is a graph showing the relationship between pEGFR(Tyr1068) and administration of 15 mg / kg of Compound 1A.

[0014] [Figure 4]Figure 4 is a graph showing the normalized bioluminescence intensity (BLI) of GBM6 orthotopic brain patient-derived xenograft tumors expressing EGFR-Viii when treated with 50 mg / kg, 15 mg / kg, or 5 mg / kg of Compound 1A.

[0015] [Figure 5] FIG. 5 is a graph showing the anti-proliferative IC50 values of compound 2B in EGFR-WT, EGFR-Viii, EGFR-Vii, EGFR-A289V, and EGFR-G598V.

[0016] [Figure 6] FIG. 6 is a graph showing the mean plasma and brain concentrations of Compound 2B (15 mg / kg), where the black bars represent plasma concentrations and the gray bars represent brain concentrations.

[0017] [Figure 7] FIG. 7 is a graph showing the relationship between pEGFR(P1068) and administration of 50 mg / kg of Compound 2B.

[0018] [Figure 8] Figure 8 is a graph showing the normalized bioluminescence intensity (BLI) of GBM6 orthotopic brain patient-derived xenograft tumors expressing EGFR-Viii when treated with 150 mg / kg, 50 mg / kg, or 15 mg / kg of Compound 2B.

[0019] [Figure 9] FIG. 9 is a graph showing the anti-proliferative IC50 values of osimertinib in EGFR-WT, EGFR-Viii, EGFR-Vii, EGFR-Vvi, and EGFR-A289V.

[0020] [Figure 10] FIG. 10 is a graph showing the mean plasma concentrations of Compound 1A in mice when administered orally (PO) at 15 mg / kg and via IV bolus at 1 mg / kg.

[0021] [Figure 11] FIG. 11 is a graph showing the mean plasma concentrations of Compound 2B in mice when administered orally (PO) at 15 mg / kg and via IV bolus at 1 mg / kg.

[0022] [Figure 12] FIG. 12 is a graph showing the survival rate of mice bearing intracranial GBM6 patient-derived tumors when orally administered 50 mg / kg of Compound 1A.

[0023] [Figure 13] FIG. 13 is a graph showing the survival rate of mice bearing intracranial GBM6 patient-derived tumors when orally administered 50 mg / kg of Compound 2B.

[0024] [Figure 14A] 14A-14B are graphs showing in vitro IC50 values against an expanded panel of EGFR mutations illustrating the spectrum of compound 2B. [Figure 14B] Same as above.

[0025] [Figure 14C] Figure 14C is a graph showing in vitro IC50 values for osimertinib against an expanded panel of EGFR mutations.

[0026] [Figure 15] FIG. 15 is a graph showing the mean concentrations of Compound 2B in the plasma and brain of mice when dosed at 15 mg / kg PO.

[0027] [Figure 16] FIG. 16 is a graph showing the mean concentrations of Compound 2B in the blood, brain, and cerebrospinal fluid (CSF) of rats when dosed at 30 mg / kg PO.

[0028] [Figure 17]FIG. 17 is a graph showing the mean concentrations of Compound 2B in the blood and cerebrospinal fluid (CSF) of dogs when dosed at 30 mg / kg PO.

[0029] [Figure 18] FIG. 18 is a graph showing % phosphorylation by Compound 2B in Ba / F3 EGFRvIII after washing.

[0030] [Figure 19A] FIG. 19A is a graph showing the relationship between pEGFR(P1068) and Compound 1 administration in mice bearing BaF3 allograft tumors expressing EGFR-Viii when administered 15 mg / kg PO.

[0031] [Figure 19B] FIG. 19B is a graph showing the relationship between pEGFR(P1068) and Compound 1A administration in mice bearing BaF3 allograft tumors expressing EGFR-Viii when administered 50 mg / kg PO.

[0032] [Figure 19C] FIG. 19C is a graph showing the relationship between administration of pEGFR(P1068) and Compound 2B in mice bearing Ba / F3 allograft tumors expressing EGFR-Viii when administered 50 mg / kg PO.

[0033] [Figure 20] FIG. 20 is a graph showing median tumor volume (mm3) in a subcutaneous GBM46 PDX-expressing EGFRvII mouse model when administered Compound 2B at 50 mg / kg.

[0034] [Figure 21] FIG. 21 is a graph showing % body weight (BW) change in a subcutaneous GBM46 PDX-expressing EGFRvII mouse model upon administration of Compound 2B at 50 mg / kg.

[0035] [Figure 22] FIG. 22 is a graph showing in vitro IC50 values for an expanded panel of EGFR variants and mutations.

[0036] [Figure 23] FIG. 23 is a graph showing in vitro IC50 values for an expanded panel of EGFR mutants for intrinsic and acquired resistance in non-small cell lung cancer (NSCLC).

[0037] [Figure 24] FIG. 24 is a graph showing the % inhibition of phosphorylation of EGFR mutant protein in Ba / F3 cells expressing the EGFR exon 19 deletion + C797S double mutation by compound 2B at 34 nM and by osimertinib at 1,000 nM, demonstrating that compound 2B has a >24 hour inhibition of pEGFR Ex19 / C797S.

[0038] [Figure 25] Figure 25 is a graph showing median tumor volume (mm3) in the Ba / F3-EGFR exon 19 deletion+C797S mouse allograft model when administered vehicle, 25 mg / kg osimertinib, 40 mg / kg Compound 2B, or 120 mg / kg Compound 2B.

[0039] [Figure 26] Figure 26 is a graph showing the maximum percent change from baseline in mean tumor volume for vehicle control, osimertinib, C797S, EGFRvii, and C595F models. Vehicle control and osimertinib were tested in the EGFR C797S model.

[0040] [Figure 27] FIG. 27 is a graph showing a schema of an exemplary study of compound 2B. DETAILED DESCRIPTION OF THE INVENTION

[0041] As used herein, the term "Compound 1" is understood to refer to a compound having the following structure: [ka]

[0042] As used herein, the term "Compound 1A" is understood to refer to a compound having the following structure: [ka]

[0043] As used herein, the term "Compound 1B" is understood to refer to a compound having the following structure: [ka]

[0044] As used herein, the term "compound 2" is understood to refer to a compound having the following structure: [ka]

[0045] As used herein, the term "compound 2A" is understood to refer to a compound having the following structure: [ka]

[0046] As used herein, the term "compound 2B" is understood to refer to a compound having the following structure: [ka]

[0047] The present disclosure relates to compounds useful as receptor tyrosine kinase (RTK) inhibitors of specific oncogenic mutants of ErbB receptors. In some embodiments of the present invention, the oncogenic mutants of ErbB receptors are also allosteric mutants of ErbB receptors. In some embodiments, the allosteric mutants may comprise or consist of ErbB receptor variants having mutations in sequences outside the ATP-binding site. In some embodiments, the allosteric mutants may comprise or consist of ErbB receptor variants having mutations in one or more sequences within exon 18, exon 19, exon 20, or the C1-C2 extracellular dimerization interface.

[0048] Mutations affecting either the intracellular catalytic domain or the extracellular ligand-binding domain of ErbB receptors can result in oncogenic activity. (The ErbB protein family consists of four members, including ErbB-1, also known as epidermal growth factor receptor (EGFR), and Erb-2, also known as HER2 in humans.) Extracellular variants of ErbB receptors in cancer, including EGFR-VIII (also EGFR-V3) and HER2-S310F, are constitutively activated in the absence of ligand, exhibit persistent signaling that is resistant to downregulation, and are both transforming and tumorigenic (Nishikawa, Ji et al. 1994, 2013; Francis, Zhang et al. 2014). Their expression is associated with metastasis and poor long-term overall survival.

[0049] Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases worldwide. NSCLC harboring EGFR mutations accounts for 10–20% of all lung cancer cases in Europe and North America and up to 50% of those in Asia. Lesser-known EGFR mutations, including EGFR-G719X, EGFR-S768I, and EGFR-L861Q, are among the most common and account for 10–20% of EGFR mutations in NSCLC. Common exon 19 deletions and L858R mutations, which account for 80–90% of EGFR mutations in NSCLC, respond to current-generation EGFR inhibitors, but resistance inevitably emerges. For example, exon 19 deletions combined with the C797S mutation (EGFR-exon 19 deletion + C797S) and EGFR-L858R + C797S mutations confer resistance to first-line treatment with current-generation irreversible inhibitors (e.g., osimertinib or lazertinib).

[0050] In glioblastoma (also glioblastoma multiforme or GBM), EGFR-VIII is expressed by 20% of tumors (Sugawa, Ekstrand et al. 1990, Brennan, Verhaak et al. 2013). EGFR-VIII expression in GBM tends to be mutually exclusive with the expression of other RTK oncogenes, which are co-expressed with EGFR variants in only 7% of GBM tumors (Furnari, Cloughesy et al. 2015). These data demonstrate how EGFR-VIII has a predominant and mutually exclusive expression pattern in GBM compared with other oncogenic drivers. EGFR-VIII is also expressed by approximately 30% of SCCHN tumors (Sok, Coppelli et al. 2006; Keller, Shroyer et al. 2010; Wheeler, Suzuki et al. 2010; Tinhofer, Klinghammer et al. 2011; Wheeler, Egloff et al. 2015) and 10% of squamous NSCLC (Ji, Zhao et al. 2006; Sasaki, Kawano et al. 2007) and is associated with resistance to current therapies, including the anti-EGFR antibody cetuximab (Sok, Coppelli et al. 2006; Tinhofer, Klinghammer et al. 2011). Normal tissues do not express this oncogenic receptor variant.

[0051] RNA sequencing data revealed that only one of several aberrantly spliced variants of EGFR was expressed in GBM tumors. The other two resulted in truncations of exons 12-13 (EGFR-Vvi) and 14-15 (EGFR-Vii). Like EGFR-Viii, EGFR-Vii is both transforming and tumorigenic. In addition to splice variants, GBM tumors also express a group of EGFR point mutations, including C620Y, A289V, and G598V, which are transforming and tumorigenic.

[0052] HER2-S310F is the most common HER2 mutation expressed in human tumors, expressed in approximately 0.5% of all tumors. HER2-S310F expression is mutually exclusive with HER2 amplification. HER2-S310F is highly oncogenic, transforming BaF3 cells (a murine interleukin-3 (IL-3)-dependent pro-B cell line) into IL-3-independent cells and promoting tumor growth in vivo.

[0053] Short insertions within exon 20 of EGFR and HER2 are expressed by lung adenocarcinoma tumors and a range of other tumors. ErbB exon 20 insertion variants are expressed by 4-5% of lung adenocarcinoma tumors. Examples include HER2-YVMA, EGFR-SVD, and EGFR-NPH. These ErbB exon 20 insertion variants are highly oncogenic, transforming BaF3 cells into an IL-3-independent state and promoting tumor growth in vivo.

[0054] ErbB inhibitor is a known treatment for some cancers.However, not all patients respond well to this treatment.Therefore, there is a long-standing need in the art for new therapies that can address the variable response of cancer patients to known therapies.The present invention can overcome some of the shortcomings of standard treatment that exist before the development of the compositions and methods disclosed herein.

[0055] Paradoxical ErbB receptor activation Although the mechanisms described herein apply to any form of cancer in which these EGFR variants of the present disclosure are expressed, the prevalence of these variants in glioblastoma (GBM) is provided as an example. Other cancers that express the EGFR variants of the present disclosure include, but are not limited to, solid tumors, epithelial cancers and / or cancers of epithelial origin, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, glioblastoma (GBM), head and neck cancer, lung cancer, and non-small cell lung cancer (NSCLC).

[0056] In GBM tumors, EGFR is frequently the target of genomic mutations and alternative splicing events that result in alterations in the extracellular dimer interface. Many tumors express two or more abnormal isoforms. This disclosure provides the mechanisms of activation for the most commonly occurring variants, EGFR-Viii, EGFR-Vii, EGFR-Vvi, EGFR-G598V, and EGFR-A289V. Each isoform / point mutation results from a unique ectodomain alteration, but all are activated by a common mechanism involving covalent, ligand-independent dimerization.

[0057] AMG-595 (Amgen) is an EGFR-Viii isoform-selective antibody that has no activity against wild-type EGFR or other splice-activating variants. Rindopepimut (Celldex) is a vaccine that selectively induces an immunological response against tumor cells that express EGFR-Viii but not wild-type EGFR or other splice-activating isoforms. Other EGFR isoforms expressed in GBM tumors (EGFR-Vii and EGFR-Vvi) are constitutively active covalent receptors, and their expression may limit the breadth and duration of therapeutic benefit of ErbB inhibitors that are selective only for EGFR-Viii. Therefore, it may be useful to exclude patients whose tumors express EGFR-Vii, EGFR-Vvi, or EGFR ectodomain point mutants from treatment with EGFR-Viii-selective therapy.

[0058] The heterogeneous genotypic expression patterns of multiple ectodomain variants of ErbB receptors in tumors suggest that small-molecule inhibitors that inhibit all variants are favorable. The family of covalently activated EGFR isoforms responds very differently to small-molecule ErbB inhibitors compared with EGFR catalytic domain mutations observed in NSCLC. Importantly, all type I inhibitors, including erlotinib, induce the formation of covalent EGFR dimers and increase EGFR phosphorylation at subsaturating concentrations, an activity that is further enhanced when the ErbB inhibitor is washed out. This manifests as a paradoxical activation of proliferation at subsaturating concentrations.

[0059] The finding of paradoxical activation of proliferation at subsaturating concentrations of type I ErbB inhibitors was further demonstrated for a series of extracellular variants of HER2 that are prevalent in several cancers, including breast and bladder. The levels of all variants present as covalently activated receptors, as well as covalent dimers, increased after treatment with type I inhibitors, including sapitinib and afatinib. Similar to covalently activated EGFR variants, subsaturating doses of type I inhibitors paradoxically increased the phosphorylation of HER2 variants and increased proliferation of cells expressing them.

[0060] In contrast to type I inhibitors, the present disclosure demonstrates that non-type I (e.g., type II) inhibitors, including neratinib, lack paradoxical activation in cells expressing ErbB ectodomain variants. Neratinib has been found to exemplify a preferred molecule that is both potent and selective for covalently activated members of the EGFR family compared to wild-type EGFR.

[0061] In summary, this disclosure provides structure / function relationships for predicting how structural variations affecting receptor regions distal to the active site can confer dramatically different responses to small molecule active site inhibitors. The findings described herein regarding the paradoxical activation of covalently activated ErbB receptor variants by type I inhibitors have important clinical implications. The data disclosed provide a mechanistic explanation for the failed clinical trials of type I inhibitors in tumor types with widespread expression of covalently activated ErbB receptors. This includes erlotinib and gefitinib in GBM tumors, erlotinib in SCCHN tumors, and sapitinib in breast tumors.

[0062] Glioblastoma Glioblastoma (GBM), a grade IV astrocytoma, is the most common form of brain cancer. The disease has a poor outcome. Surgery followed by radiation and temozolomide is the standard of care, but this treatment results in a median overall survival (OS) of only 14.6 months, with most patients not surviving five years. Over the past decade, there has been little progress in extending survival for GBM patients. In the recurrent setting, bevacizumab has demonstrated an improved progression-free survival benefit, but the addition of bevacizumab to standard-of-care therapy in the frontline setting did not confer an OS benefit.

[0063] EGFR is the most frequently altered oncogene in GBM. In addition to EGFR gene amplification, many tumors express variants generated by aberrant splicing or genomic mutations. The first recognized variant, EGFR-VIII, results from truncation of exons 2-7 and is expressed by approximately 20% of GBM tumors. EGFR-VIII is oncogenic. EGFR-VIII is constitutively activated in the absence of EGF ligand and exhibits persistent signaling that is resistant to downregulation. Thus, EGFR-VIII is both transforming and tumorigenic. EGFR-VIII expression is associated with poor long-term overall survival in GBM.

[0064] RNA sequencing data revealed that only one of several aberrantly spliced variants of EGFR was expressed in GBM tumors. The other two result in truncation of exons 12–13 (EGFR-Vvi) and 14–15 (EGFR-Vii). Like EGFR-Viii, EGFR-Vii is both transforming and tumorigenic. In addition to splice variants, GBM tumors also express a group of EGFR point mutations, including C620Y, A289V, and G598V, which are transforming and tumorigenic. The complex picture of EGFR alterations in GBM is further complicated by the finding that many tumors express more than one receptor variant.

[0065] Because expression of multiple EGFR variants in GBM results in transforming and tumorigenic activity, and because EGFR is the most frequently altered oncogene present in GBM tumors, EGFR is a particularly attractive target for small-molecule ErbB inhibitors. Following the success of small-molecule EGFR therapeutics (erlotinib, gefitinib, and afatinib) against NSCLC tumors harboring activating mutations in EGFR, these drugs were tested in GBM. Despite intensive clinical investigation of this group of ErbB inhibitors in GBM, involving >30 clinical trials and >1500 patients, all have failed to provide any benefit, even for those tumors that express EGFR-VIII. Surprisingly, some evidence suggests that erlotinib accelerated disease progression. A phase II trial evaluating erlotinib in combination with radiation and temozolomide demonstrated a median progression-free survival (mPFS) and median overall survival (mOS) of 2.8 and 8.6 months, compared with 6.9 and 14.6 months for patients receiving radiation and temozolomide alone. Another randomized phase II trial using erlotinib demonstrated that patients receiving erlotinib, including those whose tumors expressed EGFR-VIII, were less likely to progress than patients receiving standard therapy. The clinical failure of ErbB inhibitors such as erlotinib in GBM tumors has raised questions about the role of EGFR as a driver of tumor growth in GBM and led to speculation as to why ErbB inhibitors, which have been highly effective in treating EGFR mutations in lung cancer, are so ineffective in treating EGFR variants in GBM.

[0066] A unique feature of EGFR variants expressed in GBM is their location within the extracellular domain. This contrasts with activating mutations of EGFR seen in lung cancer, which are often located in the intracellular catalytic domain. EGFR consists of four extracellular domains (two ligand-binding domains and two cysteine-rich regions), a transmembrane domain, and an intracellular catalytic domain. Ligand binding promotes dimerization of the extracellular cysteine-rich domains (CR1 and CR2), an event that confers intracellular domain dimerization and activation of receptor catalytic activity. Nearly all EGFR splicing events and mutations in GBM affect the extracellular domain, particularly the two cysteine-rich regions (CR1 and CR2) that form the extracellular dimer interface. The CR region contains >40 cysteine residues, all of which form intramolecular disulfide bonds. In EGFR-VIII, truncation of exons 2–7 results in partial loss of the sequence encoding the CR1 region. The result is the loss of one cysteine from the Cys295-Cys307 pair, leaving Cys307 as a free, unpaired cysteine. In EGFR-VIII, this cysteine forms an intermolecular disulfide bond with another EGFR monomer, leading to a covalently dimerized, constitutively activated receptor. Mutation of cysteine 307 to serine (C307S) prevents the formation of covalently dimerized EGFR-VIII, which is inactive.

[0067] Some recent preclinical studies have suggested that EGFR kinase inhibitors such as erlotinib are not very effective in inhibiting EGFR-Viii, but there is no proposed mechanism for this effect.Currently, there is also a lack of understanding about the mechanisms involved in the activation of other ectodomain variants in GBM, including EGFR-Vii and EGFR-A289V.This disclosure provides the receptor activation mechanisms of the four most common ectodomain variants in GBM: EGFR-Viii, EGFR-Vii, EGFR-Vvi, EGFR-G598V and EGFR-A289V, and their impact on ErbB inhibitor activity.

[0068] The present disclosure demonstrates that, like EGFR-Viii, an additional group of EGFR variants commonly occurring in GBM (EGFR-Vii, EGFR-Vvi, EGFR-G598V, and EGFR-A289V) all exist as constitutively active covalent dimers, together forming a family of EGFR isoforms activated by this common mechanism. Furthermore, the present disclosure demonstrates that the propensity of these variants to covalently dimerize is related to the conformation of the intracellular catalytic site and confers unique activity to a class of small molecule inhibitors that bind to this distal site. Inhibitors that stabilize the active conformation of the kinase (including the type I inhibitor, erlotinib) induce covalent dimer formation for all covalently activated EGFR isoforms. This correlates with the tendency of type I inhibitors to increase EGFR phosphorylation at subsaturating concentrations, paradoxically stimulating proliferation of cells expressing covalently activated EGFR isoforms.

[0069] Neither enhanced dimerization nor paradoxical activation of EGFR is seen with small molecule inhibitors that stabilize the inactive kinase conformation (including the type II inhibitors, lapatinib and neratinib). Examples of type II inhibitors that are potent inhibitors of covalently activated EGFR isoforms and selective for this family compared with WT-EGFR have been identified.

[0070] Similar to the mutations identified for EGFR, the present disclosure identifies a group of splice events and mutations affecting the CR domains of HER2 and HER4. The present disclosure shows that this group of splice events and mutations affecting the CR domains of HER2 and HER4 exist as covalent dimers and are paradoxically activated by type I binding mode drugs. These data provide a mechanistic explanation for the failure of multiple clinical trials involving type I inhibitors, including more than 30 clinical trials of type I ErbB inhibitors in GBM. Collectively, these data indicate that tumors expressing covalently activated EGFR isoforms should be excluded from treatment with type I ErbB inhibitors, such as erlotinib, due to paradoxical activation. These data further demonstrate the utility of optimizing type II ErbB inhibitors against the covalently activated ErbB family.

[0071] Methods and Uses of the Disclosure In some aspects, the present disclosure provides a method of treating or preventing (e.g., treating) cancer in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof.

[0072] In some aspects, the present disclosure provides a method of treating or preventing (e.g., treating) cancer in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of Compound 1 (e.g., Compound 1A, or Compound 1B), or a pharmaceutically acceptable salt thereof.

[0073] In some aspects, the present disclosure provides a method of treating or preventing (e.g., treating) cancer in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of Compound 2 (e.g., Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof.

[0074] In some aspects, the present disclosure provides Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof for treating or preventing (e.g., treating) cancer in a subject in need thereof.

[0075] In some aspects, the present disclosure provides Compound 1 (e.g., Compound 1A, or Compound 1B), or a pharmaceutically acceptable salt thereof, for treating or preventing (e.g., treating) cancer in a subject in need thereof.

[0076] In some aspects, the present disclosure provides Compound 2 (e.g., Compound 2A, or Compound 2B) or a pharmaceutically acceptable salt thereof for treating or preventing (e.g., treating) cancer in a subject in need thereof.

[0077] In some aspects, the disclosure provides the use of Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing (e.g., treating) cancer in a subject in need thereof.

[0078] In some aspects, the present disclosure provides the use of Compound 1 (e.g., Compound 1A, or Compound 1B), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing (e.g., treating) cancer in a subject in need thereof.

[0079] In some aspects, the disclosure provides the use of Compound 2 (e.g., Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing (e.g., treating) cancer in a subject in need thereof.

[0080] In some embodiments, Compound 1A, Compound 1B, or a pharmaceutically acceptable salt thereof is administered.

[0081] In some embodiments, Compound 1A, a pharmaceutically acceptable salt thereof, is administered.

[0082] In some embodiments, Compound 1B, a pharmaceutically acceptable salt thereof, is administered.

[0083] In some embodiments, Compound 2A, Compound 2B, or a pharmaceutically acceptable salt thereof is administered.

[0084] In some embodiments, compound 2A, or a pharmaceutically acceptable salt thereof, is administered.

[0085] In some embodiments, compound 2B, or a pharmaceutically acceptable salt thereof, is administered.

[0086] Suitable subjects and diseases In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject is an adult human (e.g., 18 years of age or older).

[0087] In some embodiments, the subject is a mouse. In some embodiments, the subject is a rat. In some embodiments, the subject is a dog.

[0088] The compounds of the present disclosure inhibit or modulate the activity of receptor tyrosine kinases, particularly ErbB-receptors, such as, but not limited to, extracellular mutants of EGFR-VIII, EGFR-Vii, EGFR-Vvi, EGFR-A289V, and EGFR-G598V, as well as HER2-S310F. Thus, the compounds and compositions of the present disclosure can be useful as pharmaceuticals, i.e., in therapeutic methods for the prevention or treatment of cancer, more particularly as described in detail below. Thus, in a further aspect, the present disclosure provides methods for the prevention or treatment of mammals, e.g., humans, suffering from cancer, as described in detail below.

[0089] In some aspects, the present disclosure is directed to a method of inhibiting an oncogenic variant of an ErbB receptor (e.g., an oncogenic variant of EGFR), comprising administering to a subject in need thereof a therapeutically effective amount of a compound described herein.

[0090] In some aspects, the present disclosure is directed to a method of inhibiting an oncogenic variant of an ErbB receptor (e.g., an oncogenic variant of EGFR), comprising administering to a subject in need thereof a composition described herein.

[0091] In some aspects, the present disclosure is directed to a method of preventing or treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound described herein.

[0092] In some aspects, the present disclosure is directed to methods of preventing or treating cancer, comprising administering to a subject in need thereof a composition described herein.

[0093] In some aspects, the present disclosure is directed to compounds described herein for use in inhibiting oncogenic variants of ErbB receptors (eg, oncogenic variants of EGFR).

[0094] In some aspects, the present disclosure is directed to a compound described herein for use in the prevention or treatment of cancer.

[0095] In some aspects, the present disclosure is directed to a composition described herein for use in inhibiting an oncogenic variant of an ErbB receptor (eg, an oncogenic variant of EGFR).

[0096] In some aspects, the present disclosure is directed to a composition described herein for use in the prevention or treatment of cancer.

[0097] In some aspects, the present disclosure is directed to the use of a compound described herein in the manufacture of a medicament for inhibiting an oncogenic variant of an ErbB receptor (e.g., an oncogenic variant of EGFR).

[0098] In some aspects, the disclosure is directed to the use of a compound described herein in the manufacture of a medicament for preventing or treating cancer.

[0099] In some embodiments, the compound is selected from the compounds set forth in Tables 1 and 2, pharmaceutically acceptable salts, and stereoisomers thereof.

[0100] In some embodiments, the compound is selected from the compounds set forth in Table 1 and Table 2, and pharmaceutically acceptable salts thereof.

[0101] In some embodiments, the compound is selected from the compounds listed in Tables 1 and 2.

[0102] In some embodiments, the cancer comprises a solid tumor.

[0103] In some embodiments, the cancer is bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, glioblastoma (GBM), head and neck cancer, lung cancer, non-small cell lung cancer (NSCLC), or any subtype thereof.

[0104] In some embodiments, the cancer is glioblastoma (GBM) or any subtype thereof. In some embodiments, the cancer is glioblastoma.

[0105] In some embodiments, the cancer is glioblastoma, and the cancer is characterized by overexpression of EGFR.

[0106] In some embodiments, the cancer is methylated glioblastoma. In some embodiments, the cancer is unmethylated glioblastoma.

[0107] In some embodiments, the cancer is recurrent glioblastoma.

[0108] In some embodiments, the cancer is relapsed glioblastoma.

[0109] In some embodiments, the cancer is glioblastoma, and the cancer, or tumor, or cells thereof, express at least one oncogenic variant of EGFR.

[0110] In some embodiments, the cancer is recurrent glioblastoma, and the cancer, or tumor, or cells thereof, express at least one oncogenic variant of EGFR.

[0111] In some embodiments, the cancer is recurrent glioblastoma, and the cancer, or tumor, or cells thereof, express at least one oncogenic variant of EGFR.

[0112] In some embodiments, the cancer is non-small cell lung cancer (NSCLC) or any subtype thereof.

[0113] In some embodiments, the cancer is non-small cell lung cancer (NSCLC).

[0114] In some embodiments, the cancer is recurrent non-small cell lung cancer (NSCLC).

[0115] In some embodiments, the cancer is recurrent non-small cell lung cancer (NSCLC).

[0116] In some embodiments, the cancer is NSCLC and the cancer, or tumor, or cells thereof, express at least one oncogenic variant of EGFR.

[0117] In some embodiments, the cancer is recurrent NSCLC and the cancer, or tumor, or cells thereof, express at least one oncogenic variant of EGFR.

[0118] In some embodiments, the cancer is recurrent NSCLC and the cancer, or tumor, or cells thereof, express at least one oncogenic variant of EGFR.

[0119] In some embodiments, the cancer is advanced or metastatic NSCLC.

[0120] In some embodiments, the cancer is advanced or metastatic NSCLC, and the cancer, or tumor, or cells thereof, express at least one oncogenic variant of EGFR.

[0121] In some embodiments, the cancer is NSCLC and the cancer has metastasized to the central nervous system (CNS).

[0122] In some embodiments, the cancer is advanced or metastatic NSCLC, the cancer, or tumor, or cells thereof, express at least one oncogenic variant of EGFR, and the cancer has metastasized to the central nervous system (CNS).

[0123] In some embodiments, the cancer is advanced or metastatic NSCLC, the cancer, or tumor, or cells thereof, express at least one oncogenic variant of EGFR, and the cancer has not metastasized to the central nervous system (CNS).

[0124] In some embodiments, the cancer is NSCLC and the cancer has not spread to the cerebrospinal fluid (CSF).

[0125] In some embodiments, the cancer is NSCLC and the cancer has metastasized to the cerebrospinal fluid (CSF).

[0126] In some embodiments, the cancer is glioblastoma and the cancer has not spread to the cerebrospinal fluid (CSF).

[0127] In some embodiments, the cancer is glioblastoma and the cancer has metastasized to the cerebrospinal fluid (CSF).

[0128] In some embodiments, the cancer is NSCLC and the cancer has not metastasized to the brain.

[0129] In some embodiments, the cancer is NSCLC and the cancer has metastasized to the brain.

[0130] In some embodiments, the subject has a central nervous system (CNS) disease.

[0131] In some embodiments, the subject does not have any CNS disease.

[0132] In some embodiments, the subject has a leptomeningeal disease.

[0133] In some embodiments, the subject does not have any leptomeningeal disease.

[0134] In some embodiments, the cancer is NSCLC and the subject has leptomeningeal disease.

[0135] In some embodiments, the cancer is glioblastoma and the subject has leptomeningeal disease.

[0136] In some embodiments, the cancer or tumor, or cells thereof, express an oncogenic variant of an ErbB receptor.

[0137] An oncogenic variant of an ErbB receptor is understood to be an ErbB receptor protein that contains at least one oncogenic mutation and that is produced as a result of expression of a gene encoding an ErbB receptor that contains at least one oncogenic mutation.

[0138] As will be understood by those skilled in the art, from the perspective of a gene (e.g., a gene encoding an ErbB receptor), an oncogenic mutation can include, but is not limited to, mutations that result in the substitution of one amino acid for another at a particular position within an ErbB receptor, mutations that result in the insertion of one or more amino acids between two positions within an ErbB receptor, mutations that result in the deletion of another amino acid between two positions within an ErbB receptor, and mutations that result in the fusion of an ErbB receptor, or a portion thereof, with another protein or portion thereof. As will be understood by those skilled in the art, from the perspective of a gene, an oncogenic mutation can include, but is not limited to, missense mutations, nonsynonymous mutations, insertions of one or more nucleotides, deletions of one or more nucleotides, inversions, and deletion-insertions.

[0139] As will be understood by those skilled in the art, in the context of a protein (e.g., an ErbB receptor), an oncogenic mutation can include, but is not limited to, a substitution of one amino acid for another amino acid at a particular position within an ErbB receptor, an insertion of one or more amino acids between two positions within an ErbB receptor, a deletion of another amino acid between two positions within an ErbB receptor, and a fusion of an ErbB receptor or a portion thereof with another protein or portion thereof.

[0140] In some embodiments, the oncogenic variant of an ErbB receptor comprises an allosteric mutation.

[0141] In some embodiments, the oncogenic variant of an ErbB receptor is an allosteric variant of an ErbB receptor.

[0142] In some embodiments, the ErbB receptor is the epidermal growth factor receptor (EGFR) or the human epidermal growth factor receptor 2 (HER2) receptor.

[0143] In some embodiments, the ErbB receptor is epidermal growth factor receptor (EGFR).

[0144] In some embodiments, the ErbB receptor is a HER2 receptor.

[0145] In some embodiments, the ErbB receptor is a HER3 receptor.

[0146] In some embodiments, the ErbB receptor is a HER4 receptor.

[0147] In some embodiments, the cancer, or tumor, or cells thereof, express an oncogenic variant of the epidermal growth factor receptor (EGFR).

[0148] In some embodiments, the oncogenic variant of EGFR is an allosteric variant of EGFR.

[0149] In some embodiments, the oncogenic variant of EGFR comprises an allosteric mutation.

[0150] In some embodiments, the cancer, or tumor, or cells thereof, express an oncogenic variant of the HER2 receptor.

[0151] In some embodiments, the oncogenic variant of the HER2 receptor is an allosteric variant of the HER2 receptor.

[0152] In some embodiments, the oncogenic variant of the HER2 receptor comprises an allosteric mutation.

[0153] In some embodiments, the oncogenic variant of EGFR comprises an EGFR variant III (EGFR-Viii) mutation.

[0154] In some embodiments, the oncogenic variant of EGFR comprises an EGFR variant II (EGFR-Vii) mutation.

[0155] In some embodiments, the oncogenic variant of EGFR comprises an EGFR variant VI (EGFR-Vvi) mutation.

[0156] In some embodiments, the oncogenic variant of EGFR comprises a substitution of arginine (R) with lysine (K) at position 108 of SEQ ID NO:1.

[0157] In some embodiments, the oncogenic variant of EGFR comprises a substitution of arginine (R) with cysteine (C) at position 222 of SEQ ID NO:1.

[0158] In some embodiments, the oncogenic variant of EGFR comprises a substitution of alanine (A) with threonine (T) at position 289 of SEQ ID NO:1.

[0159] In some embodiments, the oncogenic variant of EGFR comprises a substitution of alanine (A) with valine (V) at position 289 of SEQ ID NO:1.

[0160] In some embodiments, the oncogenic variant of EGFR comprises a substitution of glycine (G) with valine (V) at position 598 of SEQ ID NO:1.

[0161] In some embodiments, the oncogenic variant of EGFR comprises a substitution of cysteine (C) with phenylalanine (F) at position 231 of SEQ ID NO:1.

[0162] In some embodiments, the oncogenic variant of EGFR comprises a substitution of a cysteine with a serine at position 595 of SEQ ID NO:1.

[0163] In some embodiments, the oncogenic variant of EGFR comprises a substitution of glycine (G) with valine (V) at position 598 of SEQ ID NO:1.

[0164] In some embodiments, the oncogenic variant of EGFR comprises a substitution of serine (S) with cysteine (C) at position 645 of SEQ ID NO:1.

[0165] In some embodiments, the oncogenic variant of EGFR comprises a substitution of glycine (G) at position 719 of SEQ ID NO: 1, wherein the substitution is selected from cysteine (C), aspartic acid (D), arginine (R), serine (S), or alanine (A).

[0166] In some embodiments, the oncogenic variant of EGFR comprises a substitution of glycine (G) with serine (S) at position 719 of SEQ ID NO:1.

[0167] In some embodiments, the oncogenic variant of EGFR comprises a substitution of cysteine (C) with serine (S) at position 797 of SEQ ID NO:1.

[0168] In some embodiments, the cancer or tumor, or cells thereof, express an oncogenic variant of EGFR, wherein the oncogenic variant of EGFR is an allosteric variant of EGFR, and the oncogenic variant of EGFR comprises a structural modification of EGFR, wherein the oncogenic variant of EGFR can form a covalently linked dimer, wherein the covalently linked dimer is structurally active, and wherein the covalently linked dimer enhances the activity of EGFR when contacted with a type I ErbB inhibitor. In some embodiments, the structural modification of EGFR comprises one or more of a modification of the nucleic acid sequence, amino acid sequence, secondary structure, tertiary structure, and quaternary structure. In some embodiments, the oncogenic variant comprises a mutation, a splicing event, a post-translational process, a conformational change, or any combination thereof. In some embodiments, the structural modification of EGFR occurs within the first cysteine-rich (CR1) and / or second cysteine-rich (CR2) regions of EGFR. In some embodiments, the first cysteine-rich (CR1) and / or second cysteine-rich (CR2) regions of EGFR comprise amino acid residues T211 to R334 and / or C526 to S645 of SEQ ID NO: 1, respectively. In some embodiments, the oncogenic variant of EGFR creates a physical barrier to disulfide bond formation within the CR1 and / or CR2 regions. In some embodiments, the oncogenic variant of EGFR removes a physical barrier to disulfide bond formation within the CR1 and / or CR2 regions. In some embodiments, the oncogenic variant of EGFR comprises one or more free or unpaired cysteine (C) residues located at the dimer interface of EGFR.In some embodiments, the oncogenic variant of EGFR is C190-C199, C194-C207, C215-C223, C219-C231, C232-C240, C236-C248, C251-C260, C264-C291, C295-C307, C311-C326, C329-C333, according to SEQ ID NO: 1; Contains one or more free or unpaired cysteine (C) residues at positions selected from the group consisting of C506 to C515, C510 to C523, C526 to C535, C539 to C555, C558 to C571, C562 to C579, C582 to C591, C595 to C617, C620 to C628, and C624 to C636. In some embodiments, the modification occurs at an intramolecular disulfide bond within 10 angstroms or less of a site selected from the group consisting of C190 to C199, C194 to C207, C215 to C223, C219 to C231, C232 to C240, C236 to C248, C251 to C260, C264 to C291, C295 to C307, C311 to C326, C329 to C333, C506 to C515, C510 to C523, C526 to C535, C539 to C555, C558 to C571, C562 to C579, C582 to C591, C595 to C617, C620 to C628, and C624 to C636 according to SEQ ID NO:1.

[0169] In some embodiments, the cancer or tumor, or cells thereof, express an oncogenic variant of EGFR, the oncogenic variant of EGFR being a mutation of EGFR, and the nucleotide sequence encoding the oncogenic variant of EGFR comprises a deletion or substitution comprising one or more amino acids encoding an adenosine triphosphate (ATP) binding site. In some embodiments, the ATP binding site comprises amino acids E746-A750 of SEQ ID NO: 1. In some embodiments, the ATP binding site or deletion or substitution thereof comprises L858 of SEQ ID NO: 1. In some embodiments, the deletion comprises L858 of SEQ ID NO: 1. In some embodiments, at position 858 of SEQ ID NO: 1, a leucine (L) is substituted with arginine (R) (L858R).

[0170] In some embodiments, the cancer or tumor, or cells thereof, express an oncogenic variant of EGFR, wherein the oncogenic variant of EGFR is an allosteric variant of EGFR, and the nucleotide sequence encoding the oncogenic variant of EGFR comprises an insertion within a sequence encoding exon 20, or a portion thereof. In some embodiments, the sequence encoding exon 20, or a portion thereof, comprises a sequence encoding KEILDEAYVMASVDNPHVCAR (SEQ ID NO: 7). In some embodiments, the sequence encoding exon 20, or a portion thereof, comprises a sequence encoding the C-helix, the end of the C-helix, or the post-C-helix loop. In some embodiments, the insertion comprises the amino acid sequence of ASV, SVD, NPH, or FQEA. In some embodiments, the sequence encoding exon 20, or a portion thereof, comprises one or more of the following: (a) an insertion of the amino acid sequence ASV between positions V769 and D770 of SEQ ID NO: 1; (b) an insertion of the amino acid sequence SVD between positions D770 and N771 of SEQ ID NO: 1; (c) an insertion of the amino acid sequence ASV between positions D770 and N771 of SEQ ID NO: 1;(d) insertion of the amino acid sequence NPH between positions H773 and V774 of SEQ ID NO: 1; (d) insertion of the amino acid sequence FQEA between positions A763 and Y764 of SEQ ID NO: 1; (e) insertion of the amino acid sequence PH between positions H773 and V774 of SEQ ID NO: 1; (f) insertion of the amino acid G between positions D770 and N771 of SEQ ID NO: 1; (g) insertion of the amino acid H between positions H773 and V774 of SEQ ID NO: 1; (h) insertion of the amino acid V774 between positions C770 and C771 of SEQ ID NO: 1; (i) insertion of amino acid sequence AH between positions H773 and V774 of SEQ ID NO: 1; (j) insertion of amino acid sequence SVA between positions A767 and S768 of SEQ ID NO: 1; (k) insertion of amino acid sequence GYN between positions 770 and 771 of SEQ ID NO: 1; (l) insertion of amino acid H between positions N771 and P772 of SEQ ID NO: 1; (m) insertion of amino acid Y between positions H773 and V774 of SEQ ID NO: 1. (n) insertion of the amino acid sequence PHVC between positions C775 and R776 of SEQ ID NO: 1; (o) substitution of H at position 773 of SEQ ID NO: 1 with the amino acid sequence YNPY; (p) insertion of the amino acid sequence DNP between positions P772 and H773 of SEQ ID NO: 1; (q) insertion of the amino acid sequence VDS between positions S768 and V769 of SEQ ID NO: 1; (r) insertion of the amino acid H between positions D770 and N771 of SEQ ID NO: 1; (s) insertion of N at position N of SEQ ID NO: 1 (t) insertion of the amino acid sequence PNP between positions P772 and H773 of SEQ ID NO: 1; (u) substitution of the amino acid sequence GSVDN for DN between positions 770 and 771 of SEQ ID NO: 1; (v) substitution of the amino acid sequence GYP for NP between positions 771 and 772 of SEQ ID NO: 1; (w) insertion of the amino acid G between positions N771 and P772 of SEQ ID NO: 1; (x) insertion of the amino acid sequence PNP between positions P772 and H773 of SEQ ID NO: 1;(y) insertion of the amino acid sequence GNP between positions V769 and D770 of SEQ ID NO: 1; (z) substitution of the amino acid sequence GNPHVC for VC between positions 774 and 775 of SEQ ID NO: 1; (aa) insertion of the amino acid sequence LQEA between positions A763 and Y764 of SEQ ID NO: 1; (bb) insertion of the amino acid sequence GL between positions D770 and N771 of SEQ ID NO: 1; (cc) insertion of the amino acid Y between positions D770 and N771 of SEQ ID NO: 1; (dd) insertion of the amino acid sequence NPY between positions H773 and V774 of SEQ ID NO: 1. (ee) insertion of the amino acid sequence TH between positions H773 and V774 of SEQ ID NO: 1; (ff) substitution of the amino acid sequence KGP for NP between positions 771 and 772 of SEQ ID NO: 1; (gg) substitution of the amino acid sequence SVDNP for NP between positions 771 and 772 of SEQ ID NO: 1; (hh) insertion of the amino acid sequence NN between positions N771 and P772 of SEQ ID NO: 1; (ii) insertion of the amino acid T between positions N771 and P772 of SEQ ID NO: 1; and (jj) substitution of the amino acid sequence STLASV for SV between positions 768 and 769 of SEQ ID NO: 1.

[0171] In some embodiments, the oncogenic variant of EGFR can have a mutation in exon 18 or more.

[0172] In some embodiments, the oncogenic variant of EGFR can have mutations in exon 19 or more.

[0173] In some embodiments, the oncogenic variant of EGFR can have a mutation in exon 20 or more.

[0174] In some embodiments, the cancer or tumor, or cells thereof, express an oncogenic variant of EGFR, and the oncogenic variant of EGFR is an allosteric variant of EGFR.

[0175] In some embodiments, the oncogenic variant of EGFR may be any of the following: EGFR-Viii, EGFR-Vii, EGFR-Vvi, EGFR-R222C, EGFR-R252C, EGFR-R252P, EGFR-R256Y, EGFR-T263P, EGFR-Y270C, EGFR-A289T, EGFR-A289V, EGFR-A289D, EGFR-H304Y, EGF R-G331R, EGFR-P596S, EGFR-P596L, EGFR-P596R, EGFR-G598V, EGFR-G598A, EGFR-G614D, EGFR-C620Y, EGFR-C 614W, EGFR-C628F, EGFR-C628Y, EGFR-C636Y, EGFR-S645C, EGFR-Δ660, EGFR-Δ768, EGFR-C231F, EGFR-C231F, EGFR-C595S, EGFR-D761Y, EGFR-G719C, EGFR-G719D, EGFR-G719R, EGFR-L858R, EGFR-E746-A750del, EGFR-E746-A750del+C797S, EGFR-E746-A750del+C797S+T790M, EGFR-C797S, or any combination thereof.

[0176] In some embodiments, the oncogenic variant of EGFR is selected from the following: EGFR-Viii, EGFR-Vii, EGFR-Vvi, EGFR-R108K, EGFR-R222C, EGFR-R252C, EGFR-R252P, EGFR-R256Y, EGFR-T263P, EGFR-Y270C, EGFR-A289T, EGFR-A289V, EGFR-A289D, EGFR -H304Y, EGFR-G331R, EGFR-P596S, EGFR-P596L, EGFR-P596R, EGFR-G598V, EGFR-G598A, EGFR-G614D, EGFR- C620Y, EGFR-C614W, EGFR-C628F, EGFR-C628Y, EGFR-C636Y, EGFR-S645C, EGFR-Δ660, EGFR-Δ768, EGFR-V68 9M, EGFR-N700D, EGFR-E709K, EGFR-E709Q, EGFR-E709A, EGFR-E709G, EGFR-E709V, EGFR-S768I, EGFR-C231 F, EGFR-C595S, EGFR-D761Y, EGFR-L718Q, EGFR-G719C, EGFR-G719D, EGFR-G719R, EGFR-G719A, EGFR-G719S , EGFR-G724S, EGFR-L858R, EGFR-L858R+C797S, EGFR-L861Q, EGFR-E746-A750del, EGFR-E746-A750del+C797S, EGFR-E746-A750del+S768I, EGFR-E746-A750del+C797S+T790M, EGFR-C797S, EGFR-Δ19+C797S, EGFR- Δ19+C797S+ T790M, EGFR- Δ19+S768I, EGFR-G719C+S768I, EGFR-D716Y, or any combination thereof.

[0177] In some embodiments, the oncogenic variant of EGFR comprises an insertion in exon 20, wherein the insertion comprises the amino acid sequence of ASV, SVD, NPH, or FQEA.

[0178] In some embodiments, the oncogenic variant of EGFR comprises an insertion in exon 20, wherein the insertion in exon 20 is selected from the group of insertions listed in Table 1. [Table 1]

[0179] In some embodiments, the oncogenic variant of EGFR comprises a substitution in exon 20 of EGFR.

[0180] In some embodiments, the oncogenic variant of EGFR comprises a substitution in exon 20, wherein the substitution in exon 20 is selected from the group of substitutions listed in Table 2. [Table 2]

[0181] In some embodiments, the oncogenic variant of EGFR can be any of the EGFR variants shown in Table 3. [Table 3]

[0182] In some embodiments, Δ19 can comprise a deletion of residues E746-A750 of EGFR (SEQ ID NO: 1).

[0183] In some embodiments, the cancer, or tumor, or cells thereof, express one or more of the following: (a) wild-type human epidermal growth factor receptor 2 (HER2) receptor or an oncogenic variant of the HER2 receptor.

[0184] In some embodiments, the cancer or tumor, or cells thereof, expresses a wild-type HER2 receptor, wherein the wild-type HER2 receptor comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, or 6.

[0185] In some embodiments, the cancer or tumor, or cells thereof, expresses an oncogenic variant of the HER2 receptor, and the oncogenic variant of the HER2 receptor is an allosteric variant of the HER2 receptor.

[0186] In some embodiments, the cancer, or tumor, or cells thereof, express an oncogenic variant of the HER2 receptor, wherein the oncogenic variant of the HER2 receptor is an allosteric variant of the HER2 receptor, and the oncogenic variant of the HER2 receptor comprises a substitution of serine (S) with phenylalanine (F) at position 310 of SEQ ID NO: 2 or 5.

[0187] In some embodiments, the cancer, or tumor, or cells thereof, express an oncogenic variant of the HER2 receptor, wherein the oncogenic variant of the HER2 receptor is an allosteric variant of the HER2 receptor, and the oncogenic variant of the HER2 receptor comprises a substitution of serine (S) with tyrosine (Y) at position 310 of SEQ ID NO: 2 or 5.

[0188] In some embodiments, the cancer or tumor, or cells thereof, express an oncogenic variant of the HER2 receptor, wherein the oncogenic variant of the HER2 receptor is an allosteric variant of the HER2 receptor, and the oncogenic variant of the HER2 receptor comprises a substitution of arginine (R) with glutamine (Q) at position 678 of SEQ ID NO: 2 or 5.

[0189] In some embodiments, the cancer, or tumor, or cells thereof, express an oncogenic variant of the HER2 receptor, wherein the oncogenic variant of the HER2 receptor is an allosteric variant of the HER2 receptor, and the oncogenic variant of the HER2 receptor comprises a substitution of valine (V) with leucine (L) at position 777 of SEQ ID NO: 2 or 5.

[0190] In some embodiments, the cancer, or tumor, or cells thereof, express an oncogenic variant of the HER2 receptor, wherein the oncogenic variant of the HER2 receptor is an allosteric variant of the HER2 receptor, and the oncogenic variant of the HER2 receptor comprises a substitution of valine (V) with methionine (M) at position 777 of SEQ ID NO: 2 or 5.

[0191] In some embodiments, the cancer, or tumor, or cells thereof, express an oncogenic variant of the HER2 receptor, wherein the oncogenic variant of the HER2 receptor is an allosteric variant of the HER2 receptor, and the oncogenic variant of the HER2 receptor comprises a substitution of valine (V) with isoleucine (I) at position 842 of SEQ ID NO: 2 or 5.

[0192] In some embodiments, the cancer, or tumor, or cells thereof, express an oncogenic variant of the HER2 receptor, wherein the oncogenic variant of the HER2 receptor is an allosteric variant of the HER2 receptor, and the oncogenic variant of the HER2 receptor comprises a substitution of leucine (L) with alanine (A) at position 755 of SEQ ID NO: 2 or 5.

[0193] In some embodiments, the cancer, or tumor, or cells thereof, express an oncogenic variant of the HER2 receptor, wherein the oncogenic variant of the HER2 receptor is an allosteric variant of the HER2 receptor, and the oncogenic variant of the HER2 receptor comprises a substitution of leucine (L) with proline (P) at position 755 of SEQ ID NO: 2 or 5.

[0194] In some embodiments, the cancer, or tumor, or cells thereof, express an oncogenic variant of the HER2 receptor, wherein the oncogenic variant of the HER2 receptor is an allosteric variant of the HER2 receptor, and the oncogenic variant of the HER2 receptor comprises a substitution of leucine (L) with serine (S) at position 755 of SEQ ID NO: 2 or 5.

[0195] In some embodiments, the cancer or tumor, or cells thereof, express an oncogenic variant of the HER2 receptor, wherein the oncogenic variant of the HER2 receptor is an allosteric variant of the HER2 receptor, and the nucleotide sequence encoding the oncogenic variant of the HER2 receptor comprises an insertion within a sequence encoding exon 20, or a portion thereof. In some embodiments, the sequence encoding exon 20, or a portion thereof, comprises a sequence encoding KEILDEAYVMAGVGSPYVSR (SEQ ID NO: 8). In some embodiments, the sequence encoding exon 20, or a portion thereof, comprises a sequence encoding the C-helix, the end of the C-helix, or the post-C-helix loop. In some embodiments, the insertion comprises the amino acid sequence of GSP or YVMA. In some embodiments, the sequence encoding exon 20, or a portion thereof, comprises one or more of the following: (a) an insertion of the amino acid sequence YVMA between positions A775 and G776 of SEQ ID NO:2; (b) an insertion of the amino acid sequence GSP between positions P780 and Y781 of SEQ ID NO:2; (c) an insertion of the amino acid sequence YVMA between positions A771 and Y772 of SEQ ID NO:2; (d) an insertion of the amino acid sequence YVMA between positions A775 and G776 of SEQ ID NO:2; (e) an insertion of the amino acid V between positions V777 and G778 of SEQ ID NO:2; (f) an insertion of the amino acid V between positions V777 and G778 of SEQ ID NO:2; (g) a substitution of the amino acid sequence AVGCV with GV between positions 776 and 777 of SEQ ID NO:2; (h) a substitution of the amino acid sequence LC with G between position 776 and 777 of SEQ ID NO:2; (i) substitution of G between positions 776 of SEQ ID NO:2 with the amino acid sequence LCV; (j) insertion of the amino acid sequence GSP between positions V777 and G778 of SEQ ID NO:2; (k) substitution of LRE between positions 755 and 757 of SEQ ID NO:2 with the amino acid sequence PS; (l) substitution of SP between positions 779 and 780 of SEQ ID NO:2 with the amino acid sequence CPGSP; (m) insertion of an amino acid C between positions V777 and G778 of SEQ ID NO:2; (n) substitution of AG between positions 775 and 776 of SEQ ID NO:2 with the amino acid sequence VVMA; (o) substitution of G at position 776 of SEQ ID NO:2 with the amino acid sequence VV; (p) substitution of GV between positions 776 and 777 of SEQ ID NO:2 with the amino acid sequence AVCV; (q) substitution of GV between positions 776 and 777 of SEQ ID NO:2 with the amino acid sequence VCV;(r) insertion of the amino acid G between positions G778 and S779 of SEQ ID NO:2; (s) insertion of an LRE and an amino acid sequence PK between positions 755 and 757 of SEQ ID NO:2; (t) insertion of an amino acid V between positions A775 and G776 of SEQ ID NO:2; (u) insertion of an amino acid sequence YAMA between positions A775 and G776 of SEQ ID NO:2; (v) substitution of an amino acid sequence CV for an amino acid sequence G at position 776 of SEQ ID NO:2; (w) substitution of an amino acid sequence AVCGG for an amino acid sequence GVG at positions 776 and 778 of SEQ ID NO:2; (x) substitution of an amino acid sequence AVCGG for an amino acid sequence GVG at positions 776 and 778 of SEQ ID NO:2; (y) substitution of GVG between positions 776 and 778 of SEQ ID NO: 2 with the amino acid sequence VVVG; (z) substitution of GVGS between positions 776 and 779 of SEQ ID NO: 2 with the amino acid sequence SVGG; (aa) substitution of GVGS between positions 776 and 779 of SEQ ID NO: 2 with the amino acid sequence VVGES; (bb) substitution of GV between positions 776 and 777 of SEQ ID NO: 2 with the amino acid sequence AVGSGV; (cc) substitution of GV between positions 776 and 777 of SEQ ID NO: 2 with the amino acid sequence CVC; (dd) substitution of the amino acid sequence HVC with GV between positions 776 and 777 of SEQ ID NO: 2, (ee) substitution of the amino acid sequence VAAGV with GV between positions 776 and 777 of SEQ ID NO: 2, (ff) substitution of the amino acid sequence VAGV with GV between positions 776 and 777 of SEQ ID NO: 2, (gg) substitution of the amino acid sequence VVV with GV between positions 776 and 777 of SEQ ID NO: 2, (hh) insertion of the amino acid sequence FPG between positions G778 and S779 of SEQ ID NO: 2, (ii) insertion of the amino acid sequence GS between positions S779 and P780 of SEQ ID NO: 2 insertion, (jj) substitution of VLRE between positions 754 and 757 of SEQ ID NO: 2 with amino acid sequence VPS, (kk) insertion of amino acid sequence E between positions V777 and G778 of SEQ ID NO: 2, (ll) insertion of amino acid sequence MAGV between positions V777 and G778 of SEQ ID NO: 2, (mm) insertion of amino acid S between positions V777 and G778 of SEQ ID NO: 2, (nn) insertion of amino acid sequence SCV between positions V777 and G778 of SEQ ID NO: 2, and (oo) insertion of amino acid sequence LMAY between positions Y772 and V773 of SEQ ID NO: 2.

[0196] In some embodiments, the cancer, or tumor, or cells thereof, express an oncogenic variant of the HER2 receptor, wherein the oncogenic variant of the HER2 receptor is an allosteric variant of the HER2 receptor, and the oncogenic variant of the HER2 receptor includes HER2-Δ16, HER2-C311R, HER2-S310F, p95-HER2-M611, or any combination thereof.

[0197] In some embodiments, the oncogenic variant of HER2 comprises an insertion in exon 20, wherein the insertion comprises the amino acid sequence of GSP or YVMA.

[0198] In some embodiments, the oncogenic variant of HER2 comprises an insertion in exon 20, wherein the insertion in exon 20 is selected from the group of insertions listed in Table 4. [Table 4]

[0199] In some embodiments, the oncogenic variant of HER2 comprises a substitution in exon 20 of HER2.

[0200] In some embodiments, the oncogenic variant of EGFR comprises a substitution in exon 20, wherein the substitution in exon 20 is selected from the group of substitutions listed in Table 5. [Table 5]

[0201] In some embodiments, the oncogenic variant of HER2 is any of the HER2 variants shown in Table 6. [Table 6]

[0202] In some embodiments, the cancer or tumor, or cells thereof, express an oncogenic variant of the HER3 receptor. In some embodiments, the oncogenic variant of HER3 is any of the variants shown in Table 7. [Table 7]

[0203] In some embodiments, the cancer or tumor, or cells thereof, express an oncogenic variant of the HER4 receptor. In some embodiments, the oncogenic variant of the HER4 receptor is an allosteric variant of the HER4 receptor. In some embodiments, the oncogenic variant of the HER4 receptor comprises a deletion of exon 16 (HER4-Δ16).

[0204] In some embodiments, the cancer, tumor, or cells thereof express an oncogenic variant of EGFR, wherein the sequence encoding the oncogenic variant of EGFR comprises a deletion of exon 20 or a portion thereof, and wherein the cancer, tumor, or cells thereof does not comprise a second oncogenic variation in a sequence of EGFR outside of exon 20. In some embodiments, the second oncogenic variation comprises a sequence encoding one or more of the EGFR kinase domain (KD), BRAF, NTRK, and KRAS.

[0205] In some embodiments, the cancer, tumor, or cells thereof express an oncogenic variant of EGFR, wherein the sequence encoding the oncogenic variant of EGFR comprises a deletion of exon 20 or a portion thereof, and wherein the cancer, tumor, or cells thereof do not comprise a marker indicative of responsiveness to immunotherapy.

[0206] In some embodiments, the oncogenic variant (eg, allosteric variant) or oncogenic mutation (eg, allosteric mutation) is detected by a Food and Drug Administration (FDA)-approved diagnostic method.

[0207] In some embodiments, the cancer or tumor, or cells thereof, express an oncogenic variant of phosphatidylinositol-3-kinase (PI3K). In some embodiments, the cancer or tumor, or cells thereof, express a mutant form of PI3K, which is different from the wild-type sequence of PI3K. In some embodiments, the cancer is glioblastoma, and the cancer or tumor, or cells thereof, express an oncogenic variant of PI3K. In some embodiments, the cancer is glioblastoma, and the cancer or tumor, or cells thereof, express a mutant form of PI3K, which is different from the wild-type sequence of PI3K.

[0208] An oncogenic variant of PI3K is understood to be a PI3K protein that contains at least one oncogenic mutation and that is produced as a result of expression of a gene encoding a PI3K that contains at least one oncogenic mutation.

[0209] As will be understood by those skilled in the art, from the perspective of a gene (e.g., a gene encoding PI3K), oncogenic mutations can include, but are not limited to, mutations that result in the substitution of one amino acid for another at a particular position within PI3K, but can also include mutations that result in the insertion of one or more amino acids between two positions within PI3K, mutations that result in the deletion of another amino acid between two positions within PI3K, and mutations that result in the fusion of PI3K, or a portion thereof, with another protein or portion thereof. As will be understood by those skilled in the art, from the perspective of a gene, oncogenic mutations can include, but are not limited to, missense mutations, nonsynonymous mutations, insertions of one or more nucleotides, deletions of one or more nucleotides, inversions, and deletion-insertions.

[0210] As will be understood by those skilled in the art, in terms of a protein (e.g., PI3K), oncogenic mutations can include, but are not limited to, substitution of one amino acid for another at a particular position within PI3K, insertion of one or more amino acids between two positions within PI3K, deletion of another amino acid between two positions within PI3K, and fusion of PI3K or a portion thereof with another protein or portion thereof.

[0211] In some embodiments, the cancer or tumor, or cells thereof, has an amplification of the MET gene, which encodes the receptor tyrosine kinase c-MET (also referred to as MET).

[0212] In some embodiments, the cancer is glioblastoma, and the cancer or tumor, or cells thereof, express EGFRvIII. In some embodiments, the cancer is glioblastoma, and the cancer or tumor, or cells thereof, express EGFRvII. In some embodiments, the cancer is glioblastoma, and the cancer or tumor, or cells thereof, express EGFRvVI. In some embodiments, the cancer is glioblastoma, and the cancer or tumor, or cells thereof, express EGFR-R108K. In some embodiments, the cancer is glioblastoma, and the cancer or tumor, or cells thereof, express EGFR-R222C. In some embodiments, the cancer is glioblastoma, and the cancer or tumor, or cells thereof, express EGFR-C231F. In some embodiments, the cancer is glioblastoma, and the cancer or tumor, or cells thereof, express EGFR-A289T. In some embodiments, the cancer is glioblastoma, and the cancer or tumor, or cells thereof, express EGFR-A289V. In some embodiments, the cancer is glioblastoma, and the cancer or tumor, or cells thereof, express EGFR-C595S. In some embodiments, the cancer is glioblastoma, and the cancer or tumor, or cells thereof, express EGFR-G598V. In some embodiments, the cancer is glioblastoma, and the cancer or tumor, or cells thereof, express EGFR-S645C.

[0213] In some embodiments, the cancer is NSCLC, and the cancer or tumor, or cells thereof, express EGFR-C797S. In some embodiments, the cancer is NSCLC, and the cancer or tumor, or cells thereof, express EGFR-G719S. In some embodiments, the cancer is advanced and / or metastatic NSCLC, and the cancer or tumor, or cells thereof, express EGFR-C797S. In some embodiments, the cancer is advanced and / or metastatic NSCLC, and the cancer or tumor, or cells thereof, express EGFR-G719S. In some embodiments, the cancer is NSCLC, and the cancer or tumor, or cells thereof, express EGFR-C797S, in which case the cancer or tumor, or cells thereof, are insensitive or resistant to treatment with a therapeutic agent other than the compound of the present disclosure (e.g., osimertinib or lazertinib). In some embodiments, the cancer is NSCLC and the cancer, or tumor, or cells thereof express EGFR-C797S as a resistance mechanism, in which case the cancer, or tumor, or cells thereof are insensitive or resistant to treatment with a therapeutic agent other than a compound of the present disclosure (e.g., osimertinib or lazertinib).

[0214] In some embodiments, the exon 19 deletion can include a deletion of E746-A750 (EGFR-E746-A750del).

[0215] In some embodiments, the cancer is NSCLC, and the cancer, or tumor, or cells thereof, express an oncogenic variant of EGFR that includes a deletion of exon 19. In some embodiments, the deletion of exon 19 is a deletion of E746-A750 (EGFR-E746-A750del).

[0216] In some embodiments, the cancer is NSCLC, and the cancer, or tumor, or cells thereof, express an oncogenic variant of EGFR comprising a deletion of exon 19 + C797S. In some embodiments, the deletion of exon 19 is a deletion of E746-A750 (EGFR-E746-A750del).

[0217] In some embodiments, the cancer is NSCLC, and the cancer, or tumor, or cells thereof, express an oncogenic variant of EGFR comprising a deletion of exon 19 + C797S, in which case the cancer, or tumor, or cells thereof, is insensitive to or resistant to treatment with a therapeutic agent other than the compound of the present disclosure (e.g., osimertinib or lazertinib). In some embodiments, the deletion of exon 19 is a deletion of E746-A750 (EGFR-E746-A750del). In some embodiments, the cancer is NSCLC, and the cancer, or tumor or cells thereof, express EGFR-L858R.

[0218] In some embodiments, the cancer is NSCLC, and the cancer, or tumor, or cells thereof, express EGFR-C797S+L858R.

[0219] In some embodiments, the cancer is NSCLC, and the cancer, or tumor, or cells thereof, express EGFR-C797S+L858R, in which case the cancer, or tumor, or cells thereof, is insensitive or resistant to treatment with a therapeutic agent other than a compound of the present disclosure (e.g., osimertinib or lazertinib).

[0220] In some embodiments, the cancer is NSCLC, and the cancer, or tumor, or cells thereof, express an oncogenic variant of EGFR comprising an oncogenic mutation in exon 18.

[0221] In some embodiments, the cancer is NSCLC, and the cancer, or tumor, or cells thereof, express EGFR-G719C, EGFR-G719D, EGFR-G719R, EGFR-G719A, or EGFR-G719S.

[0222] In some embodiments, the cancer is NSCLC, and the cancer, or tumor, or cells thereof, express EGFR-G719C, EGFR-G719D, EGFR-G719R, EGFR-G719A, EGFR-G719S, EGFR-S768I, EGFR-V769L, EGFR-E709G, EGFR-E709A, EGFR-D716Y, or any combination thereof.

[0223] In some embodiments, the cancer is NSCLC, and the cancer, or tumor, or cells thereof, express EGFR-S768I.

[0224] In some embodiments, the cancer is NSCLC, and the cancer, or tumor, or cells thereof, express EGFR-L861Q.

[0225] In some embodiments, the cancer is NSCLC and the cancer, or tumor, or cells thereof, have an amplification of the MET gene.

[0226] In some embodiments, the subject has not undergone surgery to treat cancer prior to treatment with a compound of the present disclosure.

[0227] In some embodiments, prior to treatment with a compound of the present disclosure, the subject has undergone one or more surgical procedures to treat cancer.

[0228] In some embodiments, the subject has undergone at least one chemoradiotherapy treatment prior to treatment with a compound of the present disclosure.

[0229] In some embodiments, the subject has recurrent GBM and has previously undergone one or more surgeries and at least one chemoradiotherapy treatment.

[0230] In some embodiments, prior to treatment with a compound of the present disclosure, the subject is treated with a therapeutic agent that is different from the compound of the present disclosure.

[0231] In some embodiments, the cancer, or tumor, or cells thereof, are insensitive or resistant to treatment with a third generation EGFR inhibitor.

[0232] In some embodiments, the cancer, or tumor, or cells thereof, is insensitive or resistant to treatment with an EGFR inhibitor other than a compound of the present disclosure.

[0233] A non-exhaustive and non-limiting list of third generation EGFR inhibitors consists of afatinib, avitinib, dacomitinib, erlotinib, gefitinib, lazertinib, mavelertinib, naquotinib, nazartinib, olmutinib, osimertinib, and rociletinib.

[0234] In some embodiments, the cancer, or tumors or cells thereof, are insensitive or resistant to treatment with one or more of afatinib, avitinib, dacomitinib, erlotinib, gefitinib, lazertinib, mavelertinib, naquotinib, nazartinib, olmutinib, osimertinib, and rociletinib.

[0235] In some embodiments, the cancer, or tumor, or cells thereof, is insensitive or resistant to treatment with osimertinib or lazertinib.

[0236] In some embodiments, the cancer is NSCLC and is insensitive or resistant to treatment with a third-generation EGFR inhibitor. In some embodiments, the cancer is NSCLC and is insensitive or resistant to treatment with a third-generation EGFR inhibitor in combination with platinum-containing chemotherapy.

[0237] In some embodiments, the cancer is NSCLC and is insensitive or resistant to treatment with a third-generation EGFR inhibitor, wherein the cancer, tumor, or cells thereof express at least one oncogenic variant of EGFR. In some embodiments, the cancer is NSCLC and is insensitive or resistant to treatment with a third-generation EGFR inhibitor in combination with platinum-containing chemotherapy, wherein the cancer, tumor, or cells thereof express at least one oncogenic variant of EGFR. In some embodiments, the oncogenic variant of EGFR can be EGFR-C797S, EGFR-L861Q, EGFR-G719C, EGFR-G719D, EGFR-G719R, EGFR-G719A, EGFR-G719S, EGFR-S768I, or EGFR-V769L.

[0238] In some embodiments, the cancer is advanced and / or metastatic NSCLC and is insensitive to or resistant to treatment with a third-generation EGFR inhibitor. In some embodiments, the cancer is advanced and / or metastatic NSCLC and is insensitive to or resistant to treatment with a third-generation EGFR inhibitor in combination with platinum-containing chemotherapy.

[0239] In some embodiments, the cancer is advanced and / or metastatic NSCLC and is insensitive or resistant to treatment with a third-generation EGFR inhibitor, wherein the cancer, tumor, or cells thereof express at least one oncogenic variant of EGFR. In some embodiments, the cancer is advanced and / or metastatic NSCLC and is insensitive or resistant to treatment with a third-generation EGFR inhibitor in combination with platinum-containing chemotherapy, wherein the cancer, tumor, or cells thereof express at least one oncogenic variant of EGFR. In some embodiments, the oncogenic variant of EGFR can be EGFR-C797S, EGFR-L861Q, EGFR-G719C, EGFR-G719D, EGFR-G719R, EGFR-G719A, EGFR-G719S, EGFR-S768I, or EGFR-V769L.

[0240] In some embodiments, the cancer is NSCLC and is insensitive or resistant to treatment with one or more of afatinib, avitinib, dacomitinib, erlotinib, gefitinib, lazertinib, mavelertinib, naquotinib, nazartinib, olmutinib, osimertinib, and rociletinib.

[0241] In some embodiments, the cancer is NSCLC and is insensitive or resistant to treatment with osimertinib or lazertinib.

[0242] In some embodiments, the cancer or tumor, or cells thereof, are insensitive or resistant to treatment with a therapeutic agent other than the compound of the present disclosure. In some embodiments, the cancer or tumor, or cells thereof, are insensitive or resistant to treatment with a type I inhibitor. In some embodiments, the cancer or tumor, or cells thereof, are insensitive or resistant to treatment with one or more of gefitinib, erlotinib, afatinib, osimertinib, necitunumab, crizotinib, alectinib, ceritinib, dabrafenib, trametinib, afatinib, sapitinib, dacomitinib, canertinib, pelitinib, WZ4002, WZ8040, WZ3146, CO-1686, and AZD9291.

[0243] In some embodiments, the subject has an adverse reaction to treatment with a therapeutic agent other than the compound of the present disclosure. In some embodiments, the subject has an adverse reaction to treatment with a type I inhibitor. In some embodiments, the subject has an adverse reaction to treatment with one or more of gefitinib, erlotinib, afatinib, osimertinib, necitunumab, crizotinib, alectinib, ceritinib, dabrafenib, trametinib, afatinib, sapitinib, dacomitinib, canertinib, pelitinib, WZ4002, WZ8040, WZ3146, CO-1686, and AZD9291. In some embodiments, the adverse reaction is activation of an oncogenic variant of EGFR, the oncogenic variant comprising a mutation in the extracellular domain of the receptor. In some embodiments, the adverse reaction is activation of an oncogenic variant of the HER2 receptor, where the oncogenic variant comprises a mutation in the extracellular domain of the receptor.

[0244] In some embodiments, the subject has previously been administered at least one initial therapy other than a compound of the present disclosure, and the subject experiences disease progression despite administration of said at least one initial therapy, wherein the initial therapy comprises administration of at least one EGFR inhibitor other than a compound of the present disclosure, at least one platinum-containing chemotherapy, at least one anti-PD-L1 therapy, or any combination thereof.

[0245] In some embodiments, the subject may have NSCLC, and the subject has previously been administered at least one initial therapy for treating said NSCLC, other than a compound of the present disclosure, and the subject experiences disease progression despite administration of said at least one initial therapy, wherein the initial therapy comprises administration of at least one EGFR inhibitor, other than a compound of the present disclosure, at least one platinum-containing chemotherapy, at least one anti-PD-L1 therapy, or any combination thereof.

[0246] In some embodiments, the subject has advanced and / or metastatic NSCLC, wherein the NSCLC, or tumor, or cells thereof, express at least one oncogenic variant of EGFR, and the subject has previously been administered at least one EGFR inhibitor, other than a compound of the present disclosure, in combination with at least one platinum-containing chemotherapy. In some embodiments, the subject has advanced and / or metastatic NSCLC, wherein the NSCLC, or tumor, or cells thereof, express at least one oncogenic variant of EGFR, and the subject has previously been administered at least one EGFR inhibitor, other than a compound of the present disclosure, in combination with at least one platinum-containing chemotherapy and at least one anti-PD-L1 therapy. In some embodiments, the at least one EGFR inhibitor can be osimertinib. In some embodiments, the at least one oncogenic variant of EGFR can be EGFR-Δ19, EGFR-L858R, EGFR-L861Q, EGFR-G719C, EGFR-G719D, EGFR-G719R, EGFR-G719A, EGFR-G719S, EGFR-S768I, EGFR-V769L, or EGFR-C797S.

[0247] In some embodiments, the subject has advanced and / or metastatic NSCLC, wherein the NSCLC, or tumor, or cells thereof, express at least one oncogenic variant of EGFR, and the subject has previously been administered at least one EGFR inhibitor, other than a compound of the present disclosure, in combination with at least one platinum-containing chemotherapy. In some embodiments, the subject has advanced and / or metastatic NSCLC, wherein the NSCLC, or tumor, or cells thereof, express at least one oncogenic variant of EGFR, and the subject has previously been administered at least one EGFR inhibitor, other than a compound of the present disclosure, in combination with at least one platinum-containing chemotherapy and at least one anti-PD-L1 therapy. In some embodiments, the at least one EGFR inhibitor can be osimertinib. In some embodiments, the at least one oncogenic variant of EGFR can be EGFR-G719C, EGFR-G719D, EGFR-G719R, EGFR-G719A, EGFR-G719S, EGFR-S768I, EGFR-V769L, EGFR-E709G, EGFR-E709A, or EGFR-D716Y. In some embodiments, the NSCLC may have metastasized to the CNS. In some embodiments, the NSCLC may not have metastasized to the CNS.

[0248] In some embodiments, the subject has advanced and / or metastatic NSCLC, wherein the NSCLC, or tumor, or cells thereof, express at least one oncogenic variant of EGFR, wherein the at least one oncogenic variant of EGFR is EGFR-C797S, and the subject has previously been administered at least one EGFR inhibitor, other than a compound of the present disclosure, in combination with at least one platinum-containing chemotherapy. In some embodiments, the subject has advanced and / or metastatic NSCLC, wherein the NSCLC, or tumor, or cells thereof, express at least one oncogenic variant of EGFR, wherein the at least one oncogenic variant of EGFR is EGFR-C797S, and the subject has previously been administered at least one EGFR inhibitor, other than a compound of the present disclosure, in combination with at least one platinum-containing chemotherapy and at least one anti-PD-L1 therapy. In some embodiments, the at least one EGFR inhibitor can be osimertinib. In some embodiments, the NSCLC may have metastasized to the CNS. In some embodiments, the NSCLC may not have metastasized to the CNS.

[0249] In some embodiments, the subject has advanced and / or metastatic NSCLC, wherein the NSCLC, or tumor, or cells thereof, express at least one oncogenic variant of EGFR, and the subject has previously been administered at least one platinum-containing chemotherapy. In some embodiments, the subject has advanced and / or metastatic NSCLC, wherein the NSCLC, or tumor, or cells thereof, express at least one oncogenic variant of EGFR, and the subject has previously been administered at least one platinum-containing chemotherapy in combination with at least one anti-PD-L1 therapy. In some embodiments, the at least one oncogenic variant of EGFR can be EGFR-G719C, EGFR-G719D, EGFR-G719R, EGFR-G719A, or EGFR-G719S. In some embodiments, the NSCLC may have metastasized to the CNS. In some embodiments, the NSCLC may not have metastasized to the CNS.

[0250] Non-limiting examples of anti-PD-L1 therapies include, but are not limited to, anti-PD-L1 antibodies known in the art (e.g., atezolizumab, avelumab, and durvalumab).

[0251] In some embodiments, the method further comprises administering to a subject in need thereof a therapeutically effective amount of a non-type I inhibitor, hi some embodiments, the non-type I inhibitor comprises a small molecule type II inhibitor.

[0252] In some embodiments, the method further comprises administering to a subject in need thereof a therapeutically effective amount of a non-type I inhibitor, hi some embodiments, the non-type I inhibitor comprises a small molecule type II inhibitor.

[0253] In some embodiments, the compound is used in combination with a therapeutically effective amount of a non-type I inhibitor. In some embodiments, the non-type I inhibitor comprises a small molecule type II inhibitor.

[0254] In some embodiments, the composition further comprises a non-type I inhibitor. In some embodiments, the non-type I inhibitor comprises a small molecule type II inhibitor.

[0255] In some embodiments, the method further comprises administering to a subject in need thereof a therapeutically effective amount of temozolomide.

[0256] In some embodiments, the compound is administered in combination with a therapeutically effective amount of temozolomide.

[0257] In some embodiments, the composition further comprises temozolomide.

[0258] In some embodiments, the compound is administered in combination with a therapeutically effective amount of a phosphatidylinositol-3-kinase (PI3K) inhibitor.

[0259] In some embodiments, the compound is administered in combination with a therapeutically effective amount of a phosphatidylinositol-3-kinase (PI3K) inhibitor.

[0260] In some embodiments, the composition further comprises a phosphatidylinositol-3-kinase (PI3K) inhibitor.

[0261] In some embodiments, the method further comprises administering to a subject in need thereof a therapeutically effective amount of amivantamab, capmatinib, or a combination thereof.

[0262] In some embodiments, the compound is administered in combination with a therapeutically effective amount of amivantamab, capmatinib, or a combination thereof.

[0263] In some embodiments, the composition further comprises amivantamab, capmatinib, or a combination thereof.

[0264] In some embodiments, the method further comprises administering to a subject in need thereof a therapeutically effective amount of osimertinib.

[0265] In some embodiments, the compound is administered in combination with a therapeutically effective amount of osimertinib.

[0266] In some embodiments, the composition further comprises osimertinib.

[0267] In some embodiments, the method further comprises administering a therapeutically effective amount of alpelisib to a subject in need thereof.

[0268] In some embodiments, the compound is administered in combination with a therapeutically effective amount of alpelisib.

[0269] In some embodiments, the composition further comprises alpelisib.

[0270] In some embodiments, the method further comprises administering to a subject in need thereof a therapeutically effective amount of paxalisib.

[0271] In some embodiments, the compound is administered in combination with a therapeutically effective amount of paxalisib.

[0272] In some embodiments, the composition further comprises paxalisib.

[0273] In some embodiments, the therapeutically effective amount reduces the severity of a sign or symptom of cancer.

[0274] In some embodiments, the symptoms of cancer include tumor grade, and reducing the severity of the symptoms includes a decrease in tumor grade.

[0275] In some embodiments, the symptom of cancer comprises tumor metastasis, and reducing the severity of the symptom comprises eliminating metastasis or reducing the rate or extent of metastasis.

[0276] In some embodiments, the symptoms of cancer include tumor volume, and the reduction in severity of the symptoms includes elimination or reduction in volume of the tumor.

[0277] In some embodiments, the symptoms of cancer include pain, and reducing the severity of the symptoms includes eliminating or reducing the pain.

[0278] In some embodiments, the therapeutically effective amount induces a period of remission.

[0279] In some embodiments, the therapeutically effective amount improves the prognosis of the subject.

[0280] Such subject uses (or methods of prevention or treatment) comprise administering to a subject in need of such prevention or treatment a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, by targeting allosteric and / or oncogenic variants of the EGFR and HER2 receptors.

[0281] Administration of Compound 1 In some embodiments, the subject is a human.

[0282] In some embodiments, Compound 1 (eg, Compound 1A or Compound 1B), or a pharmaceutically acceptable salt thereof, is administered orally.

[0283] In some embodiments, Compound 1 (e.g., Compound 1A, or Compound 1B), or a pharmaceutically acceptable salt thereof, is administered at the following doses (e.g., daily doses): about 15±10 mg, about 15±5 mg, about 15±4 mg, about 15±3 mg, about 15±2 mg, or about 15±1 mg (e.g., about 15 mg); about 25±10 mg, about 25±5 mg, about 25±4 mg, about 25±3 mg, about 25±2 mg, or about 25±1 mg (e.g., about 25 mg); about 50±10 mg, about 50±5 mg, about 50±4 mg, about 50±3 mg, about 50±2 mg, or about 50±1 mg (e.g., about 50 mg); about 100±20 mg, about 100±10 mg, about 100±5 mg, about 100±4 mg, about 100±3 mg, about 100±2 mg, or about 100±1 mg (e.g., about 100 mg), about 150±20 mg, about 150±10 mg, about 150±5 mg, about 150±4 mg, about 150±3 mg, about 150±2 mg, or about 150±1 mg (e.g., about 150 mg), about 200±20 mg, about 200±10 mg, about 200±5 mg, about 200±4 mg, about 200±3 mg, about 200±2 mg, or about 200±1 mg (e.g., about 200 mg), about 300±20 mg, about 300±10 mg, about 300±5 mg, about 300±4 mg, about 300±3 mg, about 300±2 mg, or about 300±1 mg (e.g., about 300 mg); about 400±50 mg, about 400±40 mg, about 400±30 mg, about 400±20 mg, about 400±10 mg, about 400±5 mg, about 400±4 mg, about 400±3 mg, about 400±2 mg, or about 400±1 mg (e.g., about 400 mg), about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, about 500±5 mg, about 500±4 mg, about 500±3 mg, about 500±2 mg, or about 500±1 mg (e.g., about 500 mg), about 600±50 mg, about 600±40 mg, about 600±30 mg, about 600±20 mg, about 600±10 mg, about 600±5 mg, about 600±4 mg, about 600±3 mg, about 600±2 mg, or about 600±1 mg (e.g., about 600 mg), about 800±50 mg, about 800±40 mg, about 800±30 mg, about 800±20 mg, about 800±10 mg, about 800±5 mg, about 800±4 mg, about 800±3 mg, about 800±2 mg, or about 800±1 mg (e.g., about 800 mg), or About 1000±50 mg, about 1000±40 mg, about 1000±30 mg, about 1000±20 mg, about 1000±10 mg, about 1000±5 mg, about 1000±4 mg, about 1000±3 mg, about 1000±2 mg, or about 1000±1 mg (e.g., about 1000 mg).

[0284] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 15±10 mg, about 15±5 mg, about 15±4 mg, about 15±3 mg, about 15±2 mg, or about 15±1 mg (e.g., about 15 mg).

[0285] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 25±10 mg, about 25±5 mg, about 25±4 mg, about 25±3 mg, about 25±2 mg, or about 25±1 mg (e.g., about 25 mg).

[0286] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 50±10 mg, about 50±5 mg, about 50±4 mg, about 50±3 mg, about 50±2 mg, or about 50±1 mg (e.g., about 50 mg).

[0287] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 100±20 mg, about 100±10 mg, about 100±5 mg, about 100±4 mg, about 100±3 mg, about 100±2 mg, or about 100±1 mg (e.g., about 100 mg).

[0288] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 150±20 mg, about 150±10 mg, about 150±5 mg, about 150±4 mg, about 150±3 mg, about 150±2 mg, or about 150±1 mg (e.g., about 150 mg).

[0289] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 200±20 mg, about 200±10 mg, about 200±5 mg, about 200±4 mg, about 200±3 mg, about 200±2 mg, or about 200±1 mg (e.g., about 200 mg).

[0290] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 300±20 mg, about 300±10 mg, about 300±5 mg, about 300±4 mg, about 300±3 mg, about 300±2 mg, or about 300±1 mg (e.g., about 300 mg).

[0291] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of 400±50 mg, 400±40 mg, 400±30 mg, about 400±20 mg, about 400±10 mg, about 400±5 mg, about 400±4 mg, about 400±3 mg, about 400±2 mg, or about 400±1 mg (e.g., about 400 mg).

[0292] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, about 500±5 mg, about 500±4 mg, about 500±3 mg, about 500±2 mg, or about 500±1 mg (e.g., about 500 mg).

[0293] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 600±50 mg, about 600±40 mg, about 600±30 mg, about 600±20 mg, about 600±10 mg, about 600±5 mg, about 600±4 mg, about 600±3 mg, about 600±2 mg, or about 600±1 mg (e.g., about 600 mg).

[0294] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 800±50 mg, about 800±40 mg, about 800±30 mg, about 800±20 mg, about 800±10 mg, about 800±5 mg, about 800±4 mg, about 800±3 mg, about 800±2 mg, or about 800±1 mg (e.g., about 800 mg).

[0295] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 1000±50 mg, about 1000±40 mg, about 1000±30 mg, about 1000±20 mg, about 1000±10 mg, about 1000±5 mg, about 1000±4 mg, about 1000±3 mg, about 1000±2 mg, or about 1000±1 mg (e.g., about 1000 mg).

[0296] In some embodiments, Compound 1 (e.g., Compound 1A, or Compound 1B), or a pharmaceutically acceptable salt thereof, is administered at the following doses (e.g., daily doses): about 60±10 mg / kg, about 60±5 mg / kg, about 60±4 mg / kg, about 60±3 mg / kg, about 60±2 mg / kg, or about 60±1 mg / kg (e.g., about 60 mg / kg); about 180±20 mg / kg, about 180±10 mg / kg, about 180±5 mg / kg, about 180±4 mg / kg, about 180±3 mg / kg, about 180±2 mg / kg, or about 180±1 mg / kg (e.g., about 180 mg / kg), about 600±50 mg / kg, about 600±40 mg / kg, about 600±30 mg / kg, about 600±20 mg / kg, about 600±10 mg / kg, about 600±5 mg / kg, about 600±4 mg / kg, about 600±3 mg / kg, about 600±2 mg / kg, or about 600±1 mg / kg (e.g., about 600 mg / kg), or About 1800±50 mg / kg, about 1800±40 mg / kg, about 1800±30 mg / kg, about 1800±20 mg / kg, about 1800±10 mg / kg, about 1800±5 mg / kg, about 1800±4 mg / kg, about 1800±3 mg / kg, about 1800±2 mg / kg, or about 1800±1 mg / kg (e.g., about 1800 mg / kg).

[0297] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 60±10 mg / kg, about 60±5 mg / kg, about 60±4 mg / kg, about 60±3 mg / kg, about 60±2 mg / kg, or about 60±1 mg / kg (e.g., about 60 mg / kg).

[0298] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 180±20 mg / kg, about 180±10 mg / kg, about 180±5 mg / kg, about 180±4 mg / kg, about 180±3 mg / kg, about 180±2 mg / kg, or about 180±1 mg / kg (e.g., about 180 mg / kg).

[0299] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 600±50 mg / kg, about 600±40 mg / kg, about 600±30 mg / kg, about 600±20 mg / kg, about 600±10 mg / kg, about 600±5 mg / kg, about 600±4 mg / kg, about 600±3 mg / kg, about 600±2 mg / kg, or about 600±1 mg / kg (e.g., about 600 mg / kg).

[0300] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 1800±50 mg / kg, about 1800±40 mg / kg, about 1800±30 mg / kg, about 1800±20 mg / kg, about 1800±10 mg / kg, about 1800±5 mg / kg, about 1800±4 mg / kg, about 1800±3 mg / kg, about 1800±2 mg / kg, or about 1800±1 mg / kg (e.g., about 1800 mg / kg).

[0301] In some embodiments, the subject is a mouse.

[0302] In some embodiments, the subject is a rat.

[0303] In some embodiments, the subject is a dog.

[0304] In some embodiments, Compound 1 (e.g., Compound 1A, or Compound 1B), or a pharmaceutically acceptable salt thereof, is administered at the following doses (e.g., daily doses): about 1±3 mg / kg, about 1±2 mg / kg, about 1±1 mg / kg, or about 1±0.1 mg / kg (e.g., about 1 mg / kg); about 5±3 mg / kg, about 5±2 mg / kg, or about 5±1 mg / kg (e.g., about 5 mg / kg); about 15±5 mg / kg, about 15±4 mg / kg, about 15±3 mg / kg, about 15±2 mg / kg, or about 15±1 mg / kg (e.g., about 15 mg / kg); about 30±10 mg / kg, about 30±5 mg / kg, about 30±4 mg / kg, about 30±3 mg / kg, about 30±2 mg / kg, or about 30±1 mg / kg (e.g., about 30 mg / kg); about 50±10 mg / kg, about 50±5 mg / kg, about 50±4 mg / kg, about 50±3 mg / kg, about 50±2 mg / kg, or about 50±1 mg / kg (e.g., about 50 mg / kg), or About 150±20 mg / kg, about 150±10 mg / kg, about 150±5 mg / kg, about 150±4 mg / kg, about 150±3 mg / kg, about 150±2 mg / kg, or about 150±1 mg / kg (e.g., about 150 mg / kg).

[0305] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 1±3 mg / kg, about 1±2 mg / kg, about 1±1 mg / kg, or about 1±0.1 mg / kg, (e.g., about 1 mg / kg).

[0306] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 5±3 mg / kg, about 5±2 mg / kg, or about 5±1 mg / kg (e.g., about 5 mg / kg).

[0307] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 15±5 mg / kg, about 15±4 mg / kg, about 15±3 mg / kg, about 15±2 mg / kg, or about 15±1 mg / kg (e.g., about 15 mg / kg).

[0308] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 30±10 mg / kg, about 30±5 mg / kg, about 30±4 mg / kg, about 30±3 mg / kg, about 30±2 mg / kg, or about 30±1 mg / kg (e.g., about 30 mg / kg).

[0309] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 50±10 mg / kg, about 50±5 mg / kg, about 50±4 mg / kg, about 50±3 mg / kg, about 50±2 mg / kg, or about 50±1 mg / kg (e.g., about 50 mg / kg).

[0310] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 150±20 mg / kg, about 150±10 mg / kg, about 150±5 mg / kg, about 150±4 mg / kg, about 150±3 mg / kg, about 150±2 mg / kg, or about 150±1 mg / kg (e.g., about 150 mg / kg).

[0311] In some embodiments, Compound 1 (eg, Compound 1A or Compound 1B), or a pharmaceutically acceptable salt thereof, is administered with one or more drug-free periods.

[0312] In some embodiments, Compound 1 (eg, Compound 1A or Compound 1B), or a pharmaceutically acceptable salt thereof, is administered without any drug-free period.

[0313] In some embodiments, prior to administration, the subject fasts for at least about 30 minutes, at least about 1 hour, at least about 2 hours, at least about 3 hours, at least about 4 hours, at least about 5 hours, at least about 6 hours, at least about 7 hours, at least about 8 hours, at least about 9 hours, at least about 10 hours, at least about 11 hours, or at least about 12 hours.

[0314] In some embodiments, the subject is fed for at least about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, or about 12 hours prior to administration.

[0315] Length and frequency of administration In some embodiments, Compound 1 (eg, Compound 1A or Compound 1B), or a pharmaceutically acceptable salt thereof, is administered once daily.

[0316] In some embodiments, Compound 1 (eg, Compound 1A, or Compound 1B), or a pharmaceutically acceptable salt thereof, is administered twice daily.

[0317] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered for about 21 days, about 42 days, about 63 days, about 84 days, about 105 days, about 126 days, about 147 days, about 168 days, about 189 days, or about 210 days.

[0318] In some embodiments, Compound 1 (eg, Compound 1A, or Compound 1B), or a pharmaceutically acceptable salt thereof, is administered for more than 210 days.

[0319] In some embodiments, Compound 1 (e.g., Compound 1A or Compound 1B) or a pharmaceutically acceptable salt thereof is administered until cancer progression or adverse effects (e.g., unacceptable toxicity) are observed.

[0320] In some embodiments, Compound 1 (eg, Compound 1A, or Compound 1B), or a pharmaceutically acceptable salt thereof, is administered for about 21 days.

[0321] In some embodiments, Compound 1 (eg, Compound 1A or Compound 1B), or a pharmaceutically acceptable salt thereof, is administered for about 21 days, followed by a 30-day washout period.

[0322] In some embodiments, the treatment lasts for about 1 month, about 2 months, about 3 months, about 6 months, about 9 months, about 12 months, about 15 months, about 18 months, about 21 months, or about 24 months.

[0323] In some embodiments, the treatment includes one or more treatment cycles, wherein each treatment cycle includes administering Compound 1 (e.g., Compound 1A, or Compound 1B), or a pharmaceutically acceptable salt thereof, for about 21 days, followed by a 30-day drug-free period.

[0324] Administration of Compound 2 In some embodiments, the subject is a human.

[0325] In some embodiments, Compound 2 (eg, Compound 2A or Compound 2B), or a pharmaceutically acceptable salt thereof, is administered orally.

[0326] In some embodiments, Compound 2 (e.g., Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, is administered at the following doses (e.g., daily doses): about 15±10 mg, about 15±5 mg, about 15±4 mg, about 15±3 mg, about 15±2 mg, or about 15±1 mg (e.g., about 15 mg); about 25±10 mg, about 25±5 mg, about 25±4 mg, about 25±3 mg, about 25±2 mg, or about 25±1 mg (e.g., about 25 mg); about 50±10 mg, about 50±5 mg, about 50±4 mg, about 50±3 mg, about 50±2 mg, or about 50±1 mg (e.g., about 50 mg); about 100±20 mg, about 100±10 mg, about 100±5 mg, about 100±4 mg, about 100±3 mg, about 100±2 mg, or about 100±1 mg (e.g., about 100 mg), about 150±20 mg, about 150±10 mg, about 150±5 mg, about 150±4 mg, about 150±3 mg, about 150±2 mg, or about 150±1 mg (e.g., about 150 mg), about 200±20 mg, about 200±10 mg, about 200±5 mg, about 200±4 mg, about 200±3 mg, about 200±2 mg, or about 200±1 mg (e.g., about 200 mg), about 300±20 mg, about 300±10 mg, about 300±5 mg, about 300±4 mg, about 300±3 mg, about 300±2 mg, or about 300±1 mg (e.g., about 300 mg); about 400±50 mg, about 400±40 mg, about 400±30 mg, about 400±20 mg, about 400±10 mg, about 400±5 mg, about 400±4 mg, about 400±3 mg, about 400±2 mg, or about 400±1 mg (e.g., about 400 mg), about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, about 500±5 mg, about 500±4 mg, about 500±3 mg, about 500±2 mg, or about 500±1 mg (e.g., about 500 mg), about 600±50 mg, about 600±40 mg, about 600±30 mg, about 600±20 mg, about 600±10 mg, about 600±5 mg, about 600±4 mg, about 600±3 mg, about 600±2 mg, or about 600±1 mg (e.g., about 600 mg), about 800±50 mg, about 800±40 mg, about 800±30 mg, about 800±20 mg, about 800±10 mg, about 800±5 mg, about 800±4 mg, about 800±3 mg, about 800±2 mg, or about 800±1 mg (e.g., about 800 mg), or About 1000±50 mg, about 1000±40 mg, about 1000±30 mg, about 1000±20 mg, about 1000±10 mg, about 1000±5 mg, about 1000±4 mg, about 1000±3 mg, about 1000±2 mg, or about 1000±1 mg (e.g., about 1000 mg).

[0327] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 15±10 mg, about 15±5 mg, about 15±4 mg, about 15±3 mg, about 15±2 mg, or about 15±1 mg (e.g., about 15 mg).

[0328] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 25±10 mg, about 25±5 mg, about 25±4 mg, about 25±3 mg, about 25±2 mg, or about 25±1 mg (e.g., about 25 mg).

[0329] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 50±10 mg, about 50±5 mg, about 50±4 mg, about 50±3 mg, about 50±2 mg, or about 50±1 mg (e.g., about 50 mg).

[0330] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 100±20 mg, about 100±10 mg, about 100±5 mg, about 100±4 mg, about 100±3 mg, about 100±2 mg, or about 100±1 mg (e.g., about 100 mg).

[0331] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 150±20 mg, about 150±10 mg, about 150±5 mg, about 150±4 mg, about 150±3 mg, about 150±2 mg, or about 150±1 mg (e.g., about 150 mg).

[0332] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 200±20 mg, about 200±10 mg, about 200±5 mg, about 200±4 mg, about 200±3 mg, about 200±2 mg, or about 200±1 mg (e.g., about 200 mg).

[0333] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 300±20 mg, about 300±10 mg, about 300±5 mg, about 300±4 mg, about 300±3 mg, about 300±2 mg, or about 300±1 mg (e.g., about 300 mg).

[0334] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of 400±50 mg, 400±40 mg, 400±30 mg, about 400±20 mg, about 400±10 mg, about 400±5 mg, about 400±4 mg, about 400±3 mg, about 400±2 mg, or about 400±1 mg (e.g., about 400 mg).

[0335] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, about 500±5 mg, about 500±4 mg, about 500±3 mg, about 500±2 mg, or about 500±1 mg (e.g., about 500 mg).

[0336] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 600±50 mg, about 600±40 mg, about 600±30 mg, about 600±20 mg, about 600±10 mg, about 600±5 mg, about 600±4 mg, about 600±3 mg, about 600±2 mg, or about 600±1 mg (e.g., about 600 mg).

[0337] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 800±50 mg, about 800±40 mg, about 800±30 mg, about 800±20 mg, about 800±10 mg, about 800±5 mg, about 800±4 mg, about 800±3 mg, about 800±2 mg, or about 800±1 mg (e.g., about 800 mg).

[0338] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 1000±50 mg, about 1000±40 mg, about 1000±30 mg, about 1000±20 mg, about 1000±10 mg, about 1000±5 mg, about 1000±4 mg, about 1000±3 mg, about 1000±2 mg, or about 1000±1 mg (e.g., about 1000 mg).

[0339] In some embodiments, Compound 2 (e.g., Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, is administered at the following doses (e.g., daily doses): about 60±10 mg / kg, about 60±5 mg / kg, about 60±4 mg / kg, about 60±3 mg / kg, about 60±2 mg / kg, or about 60±1 mg / kg (e.g., about 60 mg / kg); about 180±20 mg / kg, about 180±10 mg / kg, about 180±5 mg / kg, about 180±4 mg / kg, about 180±3 mg / kg, about 180±2 mg / kg, or about 180±1 mg / kg (e.g., about 180 mg / kg), about 600±50 mg / kg, about 600±40 mg / kg, about 600±30 mg / kg, about 600±20 mg / kg, about 600±10 mg / kg, about 600±5 mg / kg, about 600±4 mg / kg, about 600±3 mg / kg, about 600±2 mg / kg, or about 600±1 mg / kg (e.g., about 600 mg / kg), or About 1800±50 mg / kg, about 1800±40 mg / kg, about 1800±30 mg / kg, about 1800±20 mg / kg, about 1800±10 mg / kg, about 1800±5 mg / kg, about 1800±4 mg / kg, about 1800±3 mg / kg, about 1800±2 mg / kg, or about 1800±1 mg / kg (e.g., about 1800 mg / kg).

[0340] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 60±10 mg / kg, about 60±5 mg / kg, about 60±4 mg / kg, about 60±3 mg / kg, about 60±2 mg / kg, or about 60±1 mg / kg (e.g., about 60 mg / kg).

[0341] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 180±20 mg / kg, about 180±10 mg / kg, about 180±5 mg / kg, about 180±4 mg / kg, about 180±3 mg / kg, about 180±2 mg / kg, or about 180±1 mg / kg (e.g., about 180 mg / kg).

[0342] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 600±50 mg / kg, about 600±40 mg / kg, about 600±30 mg / kg, about 600±20 mg / kg, about 600±10 mg / kg, about 600±5 mg / kg, about 600±4 mg / kg, about 600±3 mg / kg, about 600±2 mg / kg, or about 600±1 mg / kg (e.g., about 600 mg / kg).

[0343] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 1800±50 mg / kg, about 1800±40 mg / kg, about 1800±30 mg / kg, about 1800±20 mg / kg, about 1800±10 mg / kg, about 1800±5 mg / kg, about 1800±4 mg / kg, about 1800±3 mg / kg, about 1800±2 mg / kg, or about 1800±1 mg / kg (e.g., about 1800 mg / kg).

[0344] In some embodiments, the subject is a mouse.

[0345] In some embodiments, the subject is a rat.

[0346] In some embodiments, the subject is a dog.

[0347] In some embodiments, Compound 2 (e.g., Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, is administered at the following doses (e.g., daily doses): about 1±3 mg / kg, about 1±2 mg / kg, about 1±1 mg / kg, or about 1±0.1 mg / kg (e.g., about 1 mg / kg); about 5±3 mg / kg, about 5±2 mg / kg, or about 5±1 mg / kg (e.g., about 5 mg / kg); about 15±5 mg / kg, about 15±4 mg / kg, about 15±3 mg / kg, about 15±2 mg / kg, or about 15±1 mg / kg (e.g., about 15 mg / kg); about 30±10 mg / kg, about 30±5 mg / kg, about 30±4 mg / kg, about 30±3 mg / kg, about 30±2 mg / kg, or about 30±1 mg / kg (e.g., about 30 mg / kg); about 50±10 mg / kg, about 50±5 mg / kg, about 50±4 mg / kg, about 50±3 mg / kg, about 50±2 mg / kg, or about 50±1 mg / kg (e.g., about 50 mg / kg), or About 150±20 mg / kg, about 150±10 mg / kg, about 150±5 mg / kg, about 150±4 mg / kg, about 150±3 mg / kg, about 150±2 mg / kg, or about 150±1 mg / kg (e.g., about 150 mg / kg).

[0348] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 1±3 mg / kg, about 1±2 mg / kg, about 1±1 mg / kg, or about 1±0.1 mg / kg, (e.g., about 1 mg / kg).

[0349] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 5±3 mg / kg, about 5±2 mg / kg, or about 5±1 mg / kg (e.g., about 5 mg / kg).

[0350] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 15±5 mg / kg, about 15±4 mg / kg, about 15±3 mg / kg, about 15±2 mg / kg, or about 15±1 mg / kg (e.g., about 15 mg / kg).

[0351] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 30±10 mg / kg, about 30±5 mg / kg, about 30±4 mg / kg, about 30±3 mg / kg, about 30±2 mg / kg, or about 30±1 mg / kg (e.g., about 30 mg / kg).

[0352] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 50±10 mg / kg, about 50±5 mg / kg, about 50±4 mg / kg, about 50±3 mg / kg, about 50±2 mg / kg, or about 50±1 mg / kg (e.g., about 50 mg / kg).

[0353] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered at a dose (e.g., a daily dose) of about 150±20 mg / kg, about 150±10 mg / kg, about 150±5 mg / kg, about 150±4 mg / kg, about 150±3 mg / kg, about 150±2 mg / kg, or about 150±1 mg / kg (e.g., about 150 mg / kg).

[0354] In some embodiments, Compound 2 (eg, Compound 2A or Compound 2B), or a pharmaceutically acceptable salt thereof, is administered with one or more drug-free periods.

[0355] In some embodiments, Compound 2 (eg, Compound 2A or Compound 2B), or a pharmaceutically acceptable salt thereof, is administered without any drug holiday.

[0356] In some embodiments, prior to administration, the subject fasts for at least about 30 minutes, at least about 1 hour, at least about 2 hours, at least about 3 hours, at least about 4 hours, at least about 5 hours, at least about 6 hours, at least about 7 hours, at least about 8 hours, at least about 9 hours, at least about 10 hours, at least about 11 hours, or at least about 12 hours.

[0357] In some embodiments, the subject is fed for at least about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, or about 12 hours prior to administration. Length and frequency of administration

[0358] In some embodiments, Compound 2 (eg, Compound 2A or Compound 2B), or a pharmaceutically acceptable salt thereof, is administered once daily.

[0359] In some embodiments, Compound 2 (eg, Compound 2A or Compound 2B), or a pharmaceutically acceptable salt thereof, is administered twice daily.

[0360] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered for about 21 days, about 42 days, about 63 days, about 84 days, about 105 days, about 126 days, about 147 days, about 168 days, about 189 days, or about 210 days.

[0361] In some embodiments, Compound 2 (eg, Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, is administered for more than 210 days.

[0362] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered until cancer progression or adverse effects (e.g., unacceptable toxicity) are observed.

[0363] In some embodiments, Compound 2 (eg, Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, is administered for about 21 days.

[0364] In some embodiments, Compound 2 (eg, Compound 2A or Compound 2B), or a pharmaceutically acceptable salt thereof, is administered for about 21 days, followed by a 30-day washout period.

[0365] In some embodiments, the treatment or prevention lasts for about 1 month, about 2 months, about 3 months, about 6 months, about 9 months, about 12 months, about 15 months, about 18 months, about 21 months, or about 24 months.

[0366] In some embodiments, the treatment or prevention comprises one or more treatment cycles, wherein each treatment cycle comprises administering Compound 2 (e.g., Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, for about 21 days, followed by a 30-day drug-free period. Combination with temozolomide (TMZ)

[0367] In some embodiments, the method further comprises administering a therapeutically effective amount of temozolomide.

[0368] In some embodiments, Compound 2 (eg, Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, is administered in combination with a therapeutically effective amount of temozolomide.

[0369] In some embodiments, Compound 2 (eg, Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, and temozolomide are administered simultaneously, sequentially, or alternatingly.

[0370] In some embodiments, Compound 2 (eg, Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, and temozolomide are administered simultaneously.

[0371] In some embodiments, Compound 2 (eg, Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, and temozolomide are administered sequentially.

[0372] In some embodiments, Compound 2 (eg, Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, and temozolomide are administered in close temporal proximity.

[0373] In some embodiments, Compound 2 (eg, Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, and temozolomide are administered in alternating fashion.

[0374] In some embodiments, Compound 2 (e.g., Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, and temozolomide are administered in separate formulations.

[0375] In some embodiments, Compound 2 (e.g., Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, and temozolomide are administered in a co-formulation.

[0376] In some embodiments, Compound 2 (eg, Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, and temozolomide are administered for about 28 days.

[0377] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof, and temozolomide are administered for about 28 days, about 56 days, about 84 days, about 112 days, about 140 days, about 168 days, about 196 days, about 224 days, about 252 days, or about 280 days.

[0378] In some embodiments, Compound 2 (eg, Compound 2A, or Compound 2B), or a pharmaceutically acceptable salt thereof, is administered for more than 280 days.

[0379] In some embodiments, Compound 2 (e.g., Compound 2A or Compound 2B) or a pharmaceutically acceptable salt thereof is administered until cancer progression or adverse effects (e.g., unacceptable toxicity) are observed. Exemplary Embodiments Exemplary embodiment 1. A method for treating or preventing cancer in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof. Exemplary embodiment 2. A method for treating or preventing cancer in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of Compound 1, or a pharmaceutically acceptable salt thereof. Exemplary embodiment 3. A method for treating or preventing cancer in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of Compound 2, or a pharmaceutically acceptable salt thereof. Exemplary embodiment 4. Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof for treating or preventing cancer in a subject in need thereof. Exemplary embodiment 5. Compound 1, or a pharmaceutically acceptable salt thereof, for treating or preventing cancer in a subject in need thereof. Exemplary embodiment 6. Compound 2, or a pharmaceutically acceptable salt thereof, for treating or preventing cancer in a subject in need thereof. Exemplary embodiment 7. 2. Use of Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing cancer in a subject in need thereof. Exemplary embodiment 8. 2. Use of Compound 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing cancer in a subject in need thereof. Exemplary embodiment 9. 20. Use of Compound 2, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing cancer in a subject in need thereof. Exemplary embodiment 10. 2. The method, compound, or use according to any one of the preceding embodiments, wherein the cancer is glioblastoma (GBM) or any subtype thereof. Exemplary embodiment 11. 20. The method, compound, or use according to any one of the preceding embodiments, wherein the cancer is glioblastoma. Exemplary embodiment 12. 2. The method, compound, or use according to any one of the preceding embodiments, wherein the cancer is non-small cell lung cancer (NSCLC) or any subtype thereof. Exemplary embodiment 13. 2. The method, compound, or use according to any one of the preceding embodiments, wherein the cancer is non-small cell lung cancer (NSCLC). Exemplary embodiment 14. 10. The method, compound, or use according to any one of the preceding embodiments, wherein Compound 1A, Compound 1B, or a pharmaceutically acceptable salt thereof is administered. Exemplary embodiment 15. 10. The method, compound, or use according to any one of the preceding embodiments, wherein Compound 1A, a pharmaceutically acceptable salt thereof, is administered. Exemplary embodiment 16. 10. The method, compound, or use according to any one of the preceding embodiments, wherein Compound 1B, a pharmaceutically acceptable salt thereof, is administered. Exemplary embodiment 17. 10. The method, compound, or use according to any one of the preceding embodiments, wherein Compound 2A, Compound 2B, or a pharmaceutically acceptable salt thereof is administered. Exemplary embodiment 18. 10. The method, compound, or use according to any one of the preceding embodiments, wherein compound 2A, a pharmaceutically acceptable salt thereof, is administered. Exemplary embodiment 19. 10. The method, compound, or use according to any one of the preceding embodiments, wherein compound 2B, a pharmaceutically acceptable salt thereof, is administered. Exemplary embodiment 20. 10. The method, compound, or use according to any one of the preceding embodiments, wherein the subject is a human. Exemplary embodiment 21. 10. The method, compound, or use according to any one of the preceding embodiments, wherein the subject is a mouse. Exemplary embodiment 22. The method, compound, or use according to any one of the preceding embodiments, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered in the following daily doses: about 25±10 mg, about 25±5 mg, about 25±4 mg, about 25±3 mg, about 25±2 mg, or about 25±1 mg (e.g., about 25 mg); about 50±10 mg, about 50±5 mg, about 50±4 mg, about 50±3 mg, about 50±2 mg, or about 50±1 mg (e.g., about 50 mg); about 100±20 mg, about 100±10 mg, about 100±5 mg, about 100±4 mg, about 100±3 mg, about 100±2 mg, or about 100±1 mg (e.g., about 100 mg), about 200±20 mg, about 200±10 mg, about 200±5 mg, about 200±4 mg, about 200±3 mg, about 200±2 mg, or about 200±1 mg (e.g., about 200 mg), about 300±20 mg, about 300±10 mg, about 300±5 mg, about 300±4 mg, about 300±3 mg, about 300±2 mg, or about 300±1 mg (e.g., about 300 mg); about 400±50 mg, about 400±40 mg, about 400±30 mg, about 400±20 mg, about 400±10 mg, about 400±5 mg, about 400±4 mg, about 400±3 mg, about 400±2 mg, or about 400±1 mg (e.g., about 400 mg), about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, about 500±5 mg, about 500±4 mg, about 500±3 mg, about 500±2 mg, or about 500±1 mg (e.g., about 500 mg), about 600±50 mg, about 600±40 mg, about 600±30 mg, about 600±20 mg, about 600±10 mg, about 600±5 mg, about 600±4 mg, about 600±3 mg, about 600±2 mg, or about 600±1 mg (e.g., about 600 mg), about 800±50 mg, about 800±40 mg, about 800±30 mg, about 800±20 mg, about 800±10 mg, about 800±5 mg, about 800±4 mg, about 800±3 mg, about 800±2 mg, or about 800±1 mg (e.g., about 800 mg), or About 1000±50 mg, about 1000±40 mg, about 1000±30 mg, about 1000±20 mg, about 1000±10 mg, about 1000±5 mg, about 1000±4 mg, about 1000±3 mg, about 1000±2 mg, or about 1000±1 mg (e.g., about 1000 mg). Exemplary embodiment 23. The method, compound, or use according to any one of the preceding embodiments, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered in the following daily doses: about 60±10 mg / kg, about 60±5 mg / kg, about 60±4 mg / kg, about 60±3 mg / kg, about 60±2 mg / kg, or about 60±1 mg / kg, about 180±20 mg / kg, about 180±10 mg / kg, about 180±5 mg / kg, about 180±4 mg / kg, about 180±3 mg / kg, about 180±2 mg / kg, or about 180±1 mg / kg, about 600±50 mg / kg, about 600±40 mg / kg, about 600±30 mg / kg, about 600±20 mg / kg, about 600±10 mg / kg, about 600±5 mg / kg, about 600±4 mg / kg, about 600±3 mg / kg, about 600±2 mg / kg, or about 600±1 mg / kg, or Approximately 1800±50mg / kg, approximately 1800±40mg / kg, approximately 1800±30mg / kg, approximately 1800±20mg / kg, approximately 1800±10mg / kg, approximately 1800±5mg / kg, approximately 1800±4mg / kg, approximately 1800±3mg / kg, approximately 1800±2mg / kg, or approximately 1800±1mg / kg. Exemplary embodiment 24. The method, compound, or use according to any one of the preceding embodiments, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered in the following daily doses: Approximately 1±3 mg / kg, approximately 1±2 mg / kg, approximately 1±1 mg / kg, or approximately 1±0. 1 mg / kg (e.g., about 1 mg / kg), about 5±3 mg / kg, about 5±2 mg / kg, or about 5±1 mg / kg; about 15±5 mg / kg, about 15±4 mg / kg, about 15±3 mg / kg, about 15±2 mg / kg, or about 15±1 mg / kg; about 30±10 mg / kg, about 30±5 mg / kg, about 30±4 mg / kg, about 30±3 mg / kg, or about 30±2 mg / kg, or about 30±1 mg / kg (e.g., about 30 mg / kg); about 50±10 mg / kg, about 50±5 mg / kg, about 50±4 mg / kg, about 50±3 mg / kg, about 50±2 mg / kg, or about 50±1 mg / kg, or About 150±20 mg / kg, about 150±10 mg / kg, about 150±5 mg / kg, about 150±4 mg / kg, about 150±3 mg / kg, about 150±2 mg / kg, or about 150±1 mg / kg. Exemplary embodiment 25. 2. The method, compound, or use of any one of the preceding embodiments, wherein Compound 2, or a pharmaceutically acceptable salt thereof, is administered in the following daily doses: about 25±10 mg, about 25±5 mg, about 25±4 mg, about 25±3 mg, about 25±2 mg, or about 25±1 mg (e.g., about 25 mg); about 50±10 mg, about 50±5 mg, about 50±4 mg, about 50±3 mg, about 50±2 mg, or about 50±1 mg (e.g., about 50 mg); about 100±20 mg, about 100±10 mg, about 100±5 mg, about 100±4 mg, about 100±3 mg, about 100±2 mg, or about 100±1 mg (e.g., about 100 mg), about 200±20 mg, about 200±10 mg, about 200±5 mg, about 200±4 mg, about 200±3 mg, about 200±2 mg, or about 200±1 mg (e.g., about 200 mg), about 300±20 mg, about 300±10 mg, about 300±5 mg, about 300±4 mg, about 300±3 mg, about 300±2 mg, or about 300±1 mg (e.g., about 300 mg); about 400±50 mg, about 400±40 mg, about 400±30 mg, about 400±20 mg, about 400±10 mg, about 400±5 mg, about 400±4 mg, about 400±3 mg, about 400±2 mg, or about 400±1 mg (e.g., about 400 mg), about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, about 500±5 mg, about 500±4 mg, about 500±3 mg, about 500±2 mg, or about 500±1 mg (e.g., about 500 mg), about 600±50 mg, about 600±40 mg, about 600±30 mg, about 600±20 mg, about 600±10 mg, about 600±5 mg, about 600±4 mg, about 600±3 mg, about 600±2 mg, or about 600±1 mg (e.g., about 600 mg), about 800±50 mg, about 800±40 mg, about 800±30 mg, about 800±20 mg, about 800±10 mg, about 800±5 mg, about 800±4 mg, about 800±3 mg, about 800±2 mg, or about 800±1 mg (e.g., about 800 mg), or About 1000±50 mg, about 1000±40 mg, about 1000±30 mg, about 1000±20 mg, about 1000±10 mg, about 1000±5 mg, about 1000±4 mg, about 1000±3 mg, about 1000±2 mg, or about 1000±1 mg (e.g., about 1000 mg). Exemplary embodiment 26. 2. The method, compound, or use of any one of the preceding embodiments, wherein Compound 2, or a pharmaceutically acceptable salt thereof, is administered in the following daily doses: about 60±10 mg / kg, about 60±5 mg / kg, about 60±4 mg / kg, about 60±3 mg / kg, about 60±2 mg / kg, or about 60±1 mg / kg, about 180±20 mg / kg, about 180±10 mg / kg, about 180±5 mg / kg, about 180±4 mg / kg, about 180±3 mg / kg, about 180±2 mg / kg, or about 180±1 mg / kg, about 600±50 mg / kg, about 600±40 mg / kg, about 600±30 mg / kg, about 600±20 mg / kg, about 600±10 mg / kg, about 600±5 mg / kg, about 600±4 mg / kg, about 600±3 mg / kg, about 600±2 mg / kg, or about 600±1 mg / kg, or Approximately 1800±50mg / kg, approximately 1800±40mg / kg, approximately 1800±30mg / kg, approximately 1800±20mg / kg, approximately 1800±10mg / kg, approximately 1800±5mg / kg, approximately 1800±4mg / kg, approximately 1800±3mg / kg, approximately 1800±2mg / kg, or approximately 1800±1mg / kg. Exemplary embodiment 27. 2. The method, compound, or use of any one of the preceding embodiments, wherein Compound 2, or a pharmaceutically acceptable salt thereof, is administered in the following daily doses: Approximately 1±3 mg / kg, approximately 1±2 mg / kg, approximately 1±1 mg / kg, or approximately 1±0. 1 mg / kg (e.g., about 1 mg / kg), about 5±3 mg / kg, about 5±2 mg / kg, or about 5±1 mg / kg; about 15±5 mg / kg, about 15±4 mg / kg, about 15±3 mg / kg, about 15±2 mg / kg, or about 15±1 mg / kg; about 30±10 mg / kg, about 30±5 mg / kg, about 30±4 mg / kg, about 30±3 mg / kg, or about 30±2 mg / kg, or about 30±1 mg / kg (e.g., about 30 mg / kg); about 50±10 mg / kg, about 50±5 mg / kg, about 50±4 mg / kg, about 50±3 mg / kg, about 50±2 mg / kg, or about 50±1 mg / kg, or About 150±20 mg / kg, about 150±10 mg / kg, about 150±5 mg / kg, about 150±4 mg / kg, about 150±3 mg / kg, about 150±2 mg / kg, or about 150±1 mg / kg. Exemplary embodiment 28. 10. The method of any one of the preceding embodiments, further comprising administering to a subject in need thereof a therapeutically effective amount of temozolomide. Exemplary embodiment 29. The compound of any one of the preceding embodiments, used in combination with a therapeutically effective amount of temozolomide. Exemplary embodiment 30. 10. The method of any one of the preceding embodiments, further comprising administering to a subject in need thereof a therapeutically effective amount of a phosphatidylinositol-3-kinase (PI3K) inhibitor. Exemplary embodiment 31. The compound according to any one of the preceding embodiments, used in combination with a therapeutically effective amount of a phosphatidylinositol-3-kinase (PI3K) inhibitor. Exemplary embodiment 32. 10. The method of any one of the preceding embodiments, further comprising administering to a subject in need thereof a therapeutically effective amount of amivantamab, capmatinib, or a combination thereof. Exemplary embodiment 33. The compound of any one of the preceding embodiments, used in combination with a therapeutically effective amount of amivantamab, capmatinib, or a combination thereof. Exemplary embodiment 34. 10. The method of any one of the preceding embodiments, further comprising administering to a subject in need thereof a therapeutically effective amount of osimertinib. Exemplary embodiment 35. The compound of any one of the preceding embodiments, for use in combination with a therapeutically effective amount of osimertinib. Exemplary embodiment 36. 10. The method of any one of the preceding embodiments, further comprising administering to a subject in need thereof a therapeutically effective amount of alpelisib. Exemplary embodiment 37. The compound of any one of the preceding embodiments, used in combination with a therapeutically effective amount of alpelisib. Exemplary embodiment 38. 10. The method of any one of the preceding embodiments, further comprising administering to a subject in need thereof a therapeutically effective amount of paxalisib. Exemplary embodiment 39. The compound of any one of the preceding embodiments, for use in combination with a therapeutically effective amount of paxalisib.

[0380] definition However, it is understood that the compounds disclosed herein can be represented by one particular structure. Such a particular structure should not be construed as limiting the disclosure to one or another isomer, tautomer, positional isomer, or stereoisomer, much less excluding mixtures of isomers, tautomers, positional isomers, or stereoisomers. In some embodiments, the representation of a compound herein by a particular structure is intended to encompass and refer to each of the available isomers, tautomers, positional isomers, and stereoisomers of the compound, or any mixture thereof, while also referring to the particular structure of the compound.

[0381] Furthermore, it is understood that the compounds disclosed herein can be represented without a specific structure (e.g., without a specific stereochemistry). Such representations are intended to encompass all available isomers, tautomers, positional isomers, and stereoisomers of the compound. In some embodiments, the representation of a compound herein without a specific structure is intended to refer to each of the available isomers, tautomers, positional isomers, and stereoisomers of the compound, or any mixture thereof.

[0382] As used herein, the term "isomer" means compounds that have identical molecular formulae but differ in the sequence of bonding of their atoms or the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are called "stereoisomers." Stereoisomers that are not mirror images of one another are called "diastereoisomers," and stereoisomers that are non-superimposable mirror images of each other are called "enantiomers" or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is called a "racemic mixture."

[0383] As used herein, the term "chiral center" refers to a carbon atom bonded to four non-identical substituents.

[0384] As used herein, the term "chiral isomer" means a compound having at least one chiral center. Compounds having two or more chiral centers can exist as individual diastereomers or as a mixture of diastereomers called a "diastereomeric mixture." When one chiral center is present, a stereoisomer can be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ranked according to the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al., Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511; Cahn et al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J. Chem. Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J. Chem. Educ. 1964, 41, 116).

[0385] As used herein, the term "geometric isomer" refers to diastereomers whose presence hinders rotation about a double bond or a cycloalkyl linker (e.g., 1,3-cyclobutyl). These configurations differ in their designation by the prefixes cis and trans, or Z and E, which indicate that the groups are on the same or opposite sides of the double bond in the molecule, according to the Cahn-Ingold-Prelog rules.

[0386] The terms "nucleic acid" and "polynucleotide" are used interchangeably herein to refer to single- or double-stranded RNA, DNA, or mixed polymers. Polynucleotides can include genomic sequences, extragenomic and plasmid sequences, and smaller engineered gene segments that express or can be adapted to express a polypeptide.

[0387] An "isolated nucleic acid" is a nucleic acid that is substantially separated from other genomic DNA sequences and proteins or complexes, such as ribosomes and polymerases, that naturally accompany the native sequence. The term encompasses nucleic acid sequences that have been removed from their naturally occurring environment, including recombinant or cloned DNA isolates, as well as chemically synthesized analogs or biologically synthesized analogs produced in heterologous systems. A substantially pure nucleic acid includes isolated forms of nucleic acid. Of course, this refers to the original isolated nucleic acid, but does not exclude genes or sequences later added to the isolated nucleic acid by the hand of man.

[0388] The term "polypeptide" is used in its conventional sense, i.e., as a sequence of amino acids. A polypeptide is not limited to a specific length of the product. Peptides, oligopeptides, and proteins are included within the definition of polypeptide, and such terms may be used interchangeably herein unless specifically indicated otherwise. This term also does not refer to or exclude post-expression modifications of the polypeptide, such as glycosylation, acetylation, phosphorylation, etc., both naturally occurring and non-naturally occurring, as well as other modifications known in the art. A polypeptide can be an entire protein or a portion thereof.

[0389] An "isolated polypeptide" is one that has been identified and separated and / or recovered from a component of its natural environment. In preferred embodiments, an isolated polypeptide is purified (1) to greater than 95% by weight of the polypeptide as determined by the Lowry method, most preferably to greater than 99% by weight, (2) sufficiently to obtain at least 15 residues of N-terminal or internal amino acid sequence using a spinning cup sequencer, or (3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions using Coomassie blue, or preferably silver staining. Isolated polypeptides include polypeptides in situ within recombinant cells, since at least one component of the polypeptide's natural environment will be absent. Ordinarily, however, isolated polypeptides will be prepared by at least one purification step.

[0390] A "native sequence" polynucleotide is one that has the same nucleotide sequence as a polynucleotide derived from nature. A "native sequence" polypeptide is one (e.g., EGFR) that has the same amino acid sequence as a polypeptide derived from nature (e.g., from any species). Such native sequence polynucleotides and polypeptides can be isolated from nature or produced by recombinant or synthetic means.

[0391] A "variant" of a polynucleotide, as that term is used herein, is a polynucleotide that typically differs from the polynucleotides specifically disclosed herein in one or more substitutions, deletions, additions, and / or insertions.

[0392] A "variant" of a polypeptide, as that term is used herein, is a polypeptide that typically differs from a polypeptide specifically disclosed herein in one or more substitutions, deletions, additions, and / or insertions, or inversions. Such variants may be naturally occurring, non-naturally occurring, or synthetically produced.

[0393] Mutations (or variants) of EGFR of the present disclosure can include one or more substitutions, deletions, additions, and / or insertions, or inversions in the amino acid sequence that alter the function of the resulting protein. Mutations can be detected, for example, by comparison or alignment of the nucleic acid or amino acid sequence with a wild-type sequence.

[0394] When comparing polynucleotide and polypeptide sequences, two sequences are said to be "identical" if the nucleotide or amino acid sequences in the two sequences are the same when aligned for maximum correspondence, as described below. Comparison between two sequences is typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. As used herein, a "comparison window" refers to a segment of at least about 20 consecutive positions, usually 30 to about 75, 40 to about 50 consecutive positions, within which the two sequences can be optimally aligned and compared to a reference sequence of the same number of consecutive positions.

[0395] Optimal alignment of sequences for comparison can be performed using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI) using default parameters, which embodies several alignment schemes described in the following references: Dayhoff, MO (1978) A model of evolutionary change in protein-Matrices for detecting distant relationships. In Dayhoff, MO (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenes pp. 626-645 Methods in Enzymology vol.183, Academic Press, Inc., San Diego, CA; Higgins, DGand Sharp, PM (1989) CABIOS 5:151-153; Myers, EWand Muller W. (1988) CABIOS 4:11-17; Robinson, ED (1971) Comb. Theor 11:105;Santou,N.Nes,M.(1987)Mol.Biol.Evol.4:406-425;Sneath,PHAand Sokal,RR(1973)Numerical Taxonomy-the Principles and Practice of Numerical Taxonomy,Freeman Press,San Francisco,CA;Wilbur,WJand Lipman, DJ (1983) Proc. Natl. Acad., Sci. USA 80:726-730.

[0396] Alternatively, optimal sequence alignment for comparison may be performed by the local identity algorithm of Smith and Waterman (1981) Add. APL. Math 2:482, the identity alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, the search for similarity method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444, computer-implemented algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by visual inspection.

[0397] One preferred example of algorithms suitable for determining percent sequence identity and percent sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) Nucl. Acids Res. 25:3389-3402 and Altschul et al. (1990) J. Mol. Biol. 215:403-410, respectively. BLAST and BLAST 2.0 can be used, for example, with the parameters described herein to determine percent sequence identity of the polynucleotides and polypeptides of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.

[0398] In one example, cumulative scores can be calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). Extension of word hits in each direction is stopped when the cumulative alignment score falls below its maximum achieved value by an amount X; when the cumulative score falls below zero due to the accumulation of one or more negative-scoring residue alignments; or when either sequence reaches its end. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses a word length (W) of 11, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915). The algorithm uses as defaults a word length of 50, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

[0399] For amino acid sequences, a score matrix may be used to calculate the cumulative score. Extension of word hits in each direction is halted when the cumulative alignment score falls off by the amount X from its maximum achieved value, when the cumulative score falls below zero due to the accumulation of one or more negative-scoring residue alignments, or when either sequence reaches its end. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.

[0400] In one approach, "percent sequence identity" is determined by comparing two optimally aligned sequences over a comparison window of at least 20 positions, where the portion of the polynucleotide or polypeptide sequence in the comparison window may contain 20% or less, typically 5-15%, or 10-12% additions or deletions (i.e., gaps) compared to the reference sequence (which does not contain additions or deletions) due to optimal alignment of the two sequences. The percentage of sequence identity is calculated by determining the number of positions where the same nucleic acid base or amino acid residue occurs in both sequences to obtain the number of matching positions, dividing the number of matching positions by the total number of positions in the reference sequence (i.e., the window size), and multiplying the result by 100 to obtain the percentage of sequence identity.

[0401] The wild-type EGFR sequence of the present disclosure may comprise or consist of the following amino acid sequence: 1 mrpsgtagaa llallaalcp asraleekkv cqgtsnkltq lgtfedhfls lqrmfnncev 61 vlgnleityv qrnydlsflk tiqevagyvl ialntverip lenlqiirgn myyensyala 121 vlsnydankt glkelpmrnl qeilhgavrf snnpalcnve siqwrdivss dflsnmsmdf 181 qnhlgscqkc dpscpngscw gageencqkl tkiicaqqcs grcrgkspsd cchnqcaagc 241 tgpresdclv crkfrdeatc kdtcpplmly npttyqmdvn pegkysfgat cvkkcprnyv 301 vtdhgscvra cgadsyemee dgvrkckkce gpcrkvcngi gigefkdsls inatnikhfk 361 nctsisgdlh ilpvafrgds fthtppldpq eldilktvke itgflliqaw penrtdlhaf 421 enleiirgrt kqhgqfslav vslnitslgl rslkeisdgd viisgnknlc yantinwkkl 481 fgtsgqktki isnrgensck atgqvchalc spegcwgpep rdcvscrnvs rgrecvdkck 541 llegeprefv enseciqchp eclpqamnit ctgrgpdnci qcahyidgph cvktcpagvm 601 genntlvwky adaghvchlc hpnctygctg pglegcptng pkipsiatgm vgalllllvv 661 algiglfmrr rhivrkrtlr rllqerelve pltpsgeapn qallrilket efkkikvlgs 721 gafgtvykgl wipegekvki pvaikelrea tspkankeil deayvmasvd nphvcrllgi 781 cltstvqlit qlmpfgclld yvrehkdnig sqyllnwcvq iakgmnyled rrlvhrdlaa 841 rnvlvktpqh vkitdfglak llgaeekeyh aeggkvpikw malesilhri ythqsdvwsy 901 gvtvwelmtf gskpydgipa seissilekg erlpqppict idvymimvkc wmidadsrpk 961 freliiefsk mardpqrylv iqgdermhlp sptdsnfyra lmdeedmddv vdadeylipq 1021 qgffsspsts rtpllsslsa tsnnstvaci drnglqscpi kedsflqrys sdptgalted 1081 siddtflpvp eyinqsvpkr pagsvqnpvy hnqplnpaps rdphyqdphs tavgnpeyln 1141 tvqptcvnst fdspahwaqk gshqisldnp dyqqdffpke akpngifkgs taenaeylrv 1201 apqssefiga (SEQ ID NO: 1, corresponds to epidermal growth factor receptor [Homo sapiens] and Genbank accession number CAA25240).

[0402] The wild-type HER2 receptor sequence of the present disclosure may comprise or consist of the following amino acid sequence: 1 melaalcrwg lllallppga astqvctgtd mklrlpaspe thldmlrhly qgcqvvqgnl 61 eltylptnas lsflqdiqev qgyvliahnq vrqvplqrlr ivrgtqlfed nyalavldng 121 dplnnttpvt gaspgglrel qlrslteilk ggvliqrnpq lcyqdtilwk difhknnqla 181 ltlidtnrsr achpcspmck gsrcwgesse dcqsltrttvc aggcarckgp lptdccheqc 241 aagctgpkhs dclaclhfnh sgicelhcpa lvtyntdtfe smpnpegryt fgascvtacp 301 ynylstdvgs ctlvcplhnq evtaedgtqr cekcskpcar vcyglgmehl revravtsan 361 iqefagckki fgslaflpes fdgdpasnta plqpeqlqvf etleeitgyl yisawpdslp 421 dlsvfqnlqv irgrilhnga ysltlqglgi swlglrslre lgsglalihh nthlcfvhtv 481 pwdqlfrnph qallhtanrp edecvgegla chqlcarghc wgpgptqcvn csqflrgqec 541 veecrvlqgl preyvnarhc lpchpecqpq ngsvtcfgpe adqcvacahy kdppfcvarc 601 psgvkpdlsy mpiwkfpdee gacqpcpinc thscvdlddk gcpaeqrasp ltsiisavvg 661 illvvvlgvv fgilikrrqq kirkytmrrl lqetelvepl tpsgampnqa qmrilketel 721 rkvkvlgsga fgtvykgiwi pdgenvkipv aikvlrents pkankeilde ayvmagvgsp 781 yvsrllgicl tstvqlvtql mpygclldhv renrgrlgsq dllnwcmqia kgmsyledvr 841 lvhrdlaarn vlvkspnhvk itdfglarll dideteyhad ggkvpikwma lesilrrrft 901 hqsdvwsygv tvwelmtfga kpydgipare ipdllekger lpqppictid vymimvkcwm 961 idsecrprfr elvsefsrma rdpqrfvviq nedlgpaspl dstfyrslle dddmgdlvda 1021 eeylvpqqgf fcpdpapgag gmvhhrhrss strsgggdlt lglepseeea prsplapseg 1081 agsdvfdgdl gmgaakglqs lpthdpsplq rysedptvpl psetdgyvap ltcspqpeyv 1141 nqpdvrpqpp spregplpaa rpagatlerp ktlspgkngv vkdvfafgga venpeyltpq 1201 ggaapqphpp pafspafdnl yywdqdpper gappstfkgt ptaenpeylg ldvpv (SEQ ID NO: 2, corresponds to receptor tyrosine-protein kinase erbB-2 isoform a precursor [Homo sapiens] and GenBank accession number NP_004439).

[0403] The wild-type HER2 receptor sequence of the present disclosure may comprise or consist of the following amino acid sequence: 1 mklrlpaspe thldmlrhly qgcqvvqgnl eltylptnas lsflqdiqev qgyvliahnq 61 vrqvplqrlr ivrgtqlfed nyalavldng dplnnttpvt gaspgglrel qlrslteilk 121 ggvliqrnpq lcyqdtilwk difhknnqla ltlidtnrsr achpcspmck gsrcwgesse 181 dcqsltrttvc aggcarckgp lptdccheqc aagctgpkhs dclaclhfnh sgicelhcpa 241 lvtyntdtfe smpnpegryt fgascvtacp ynylstdvgs ctlvcplhnq evtaedgtqr 301 cekcskpcar vcyglgmehl revravtsan iqefagckki fgslaflpes fdgdpasnta 361 plqpeqlqvf etleeitgyl yisawpdslp dlsvfqnlqv irgrilhnga ysltlqglgi 421 swlglrslre lgsglalihh nthlcfvhtv pwdqlfrnph qallhtanrp edecvgegla 481 chqlcarghc wgpgptqcvn csqflrgqec veecrvlqgl preyvnarhc lpchpecqpq 541 ngsvtcfgpe adqcvacahy kdppfcvarc psgvkpdlsy mpiwkfpdee gacqpcpinc 601 thscvdlddk gcpaeqrasp ltsiisavvg illvvvlgvv fgilikrrqq kirkytmrrl 661 lqetelvepl tpsgampnqa qmrilketel rkvkvlgsga fgtvykgiwi pdgenvkipv 721 aikvlrents pkankeilde ayvmagvgsp yvsrllgicl tstvqlvtql mpygclldhv 781 renrgrlgsq dllnwcmqia kgmsyledvr lvhrdlaarn vlvkspnhvk itdfglarll 841 dideteyhad ggkvpikwma lesilrrrft hqsdvwsygv tvwelmtfga kpydgipare 901 ipdllekger lpqppictid vymimvkcwm idsecrprfr elvsefsrma rdpqrfvviq 961 nedlgpaspl dstfyrslle dddmgdlvda eeylvpqqgf fcpdpapgag gmvhhhrhrss 1021 strsgggdlt lglepseeea prsplapseg agsdvfdgdl gmgaakglqs lpthdpsplq 1081 rysedptvpl psetdgyvap ltcspqpeyv nqpdvrpqpp spregplpaa rpagatlerp 1141 ktlspgkngv vkdvfafgga venpeyltpq ggaapqphpp pafspafdnl yywdqdpper 1201 gappstfkgt ptaenpeylg ldvpv (SEQ ID NO: 3, corresponds to receptor tyrosine-protein kinase erbB-2 isoform b [Homo sapiens] and GenBank accession number NP_001005862).

[0404] The wild-type HER2 receptor sequence of the present disclosure may comprise or consist of the following amino acid sequence: 1 mprgswkpqv ctgtdmklrl paspethldm lrhlyqgcqv vqgnleltyl ptnaslsflq 61 diqevqgyvl iahnqvrqvp lqrlrivrgt qlfednyala vldngdplnn ttpvtgaspg 121 glrelqlrsl teilkggvli qrnpqlcyqd tilwkdifhk nnqlaltlid tnrsrachpc 181 spmckgsrcw gessedcqsl trtvcaggca rckgplptdc cheqcaagct gpkhsdclac 241 lhfnhsgice lhcpalvtyn tdtfesmpnp egrytfgasc vtacpynyls tdvgsctlvc 301 plhnqevtae dgtqrcekcs kpcarvcygl gmehlrevra vtsaniqefa gckkifgsla 361 flpesfdgdp asntaplqpe qlqvfetlee itgylyisaw pdslpdlsvf qnlqvirgri 421 lhngaysltl qglgiswlgl rslrelgsgl alihhnthlc fvhtvpwdql frnphqallh 481 tanrpedecv geglachqlc arghcwgpgp tqcvncsqfl rgqecveecr vlqglpreyv 541 narhclpchp ecqpqngsvt cfgpeadqcv acahykdppf cvarcpsgvk pdlsympiwk 601 fpdeegacqp cpincthscv dlddkgcpae qraspltsii savvgillvv vlgvvfgili 661 krrqqkirky tmrrllqete lvepltpsga mpnqaqmril ketelrkvkv lgsgafgtvy 721 kgiwipdgen vkipvaikvl rentspkank eildeayvma gvgspyvsrl lgicltstvq 781 lvtqlmpygc lldhvrenrg rlgsqdllnw cmqiakgmsy ledvrlvhrd laarnvlvks 841 pnhvkitdfg larlldidet eyhadggkvp ikwmalesil rrrfthqsdv wsygvtvwel 901 mtfgakpydg ipareipdll ekgerlpqpp ictidvymim vkcwmidsec rprfrelvse 961 fsrmardpqr fvviqnedlg paspldstfy rslledddmg dlvdaeeylv pqqgffcpdp 1021 apgaggmvhh rhrssstrsg ggdltlglep seeeaprspl apsegagsdv fdgdlgmgaa 1081 kglqslpthd psplqrysed ptvplpsetd gyvapltcsp qpeyvnqpdv rpqppspreg 1141 plpaarpaga tlerpktlsp gkngvvkdvf afggavenpe yltpqggaap qphpppafsp 1201 afdnlyywdq dppergapps tfkgtptaen peylgldvpv (SEQ ID NO: 4, corresponds to receptor tyrosine-protein kinase erbB-2 isoform c [Homo sapiens] and GenBank accession number NP_001276865).

[0405] The wild-type HER2 receptor sequence of the present disclosure may comprise or consist of the following amino acid sequence: 1 melaalcrwg lllallppga astqvctgtd mklrlpaspe thldmlrhly qgcqvvqgnl 61 eltylptnas lsflqdiqev qgyvliahnq vrqvplqrlr ivrgtqlfed nyalavldng 121 dplnnttpvt gaspgglrel qlrslteilk ggvliqrnpq lcyqdtilwk difhknnqla 181 ltlidtnrsr achpcspmck gsrcwgesse dcqsltrtvc aggcarckgp lptdccheqc 241 aagctgpkhs dclaclhfnh sgicelhcpa lvtyntdtfe smpnpegryt fgascvtacp 301 ynylstdvgs ctlvcplhnq evtaedgtqr cekcskpcar vcyglgmehl revravtsan 361 iqefagckki fgslaflpes fdgdpasnta plqpeqlqvf etleeitgyl yisawpdslp 421 dlsvfqnlqv irgrilhnga ysltlqglgi swlglrslre lgsglalihh nthlcfvhtv 481 pwdqlfrnph qallhtanrp edecvgegla chqlcarghc wgpgptqcvn csqflrgqec 541 veecrvlqgl preyvnarhc lpchpecqpq ngsvtcfgpe adqcvacahy kdppfcvarc 601 psgvkpdlsy mpiwkfpdee gacqpcpinc thscvdlddk gcpaeqrasp ltsiisavvg 661 illvvvlgvv fgilikrrqq kirkytmrrl lqetelvepl tpsgampnqa qmrilketel 721 rkvkvlgsga fgtvykgiwi pdgenvkipv aikvlrents pkankeilde ayvmagvgsp 781 yvsrllgicl tstvqlvtql mpygclldhv renrgrlgsq dllnwcmqia kgmsyledvr 841 lvhrdlaarn vlvkspnhvk itdfglarll dideteyhad ggkvpikwma lesilrrrft 901 hqsdvwsygv tvwelmtfga kpydgipare ipdllekger lpqppictid vymimvkcwm 961 idsecrprfr elvsefsrma rdpqrfvviq nedlgpaspl dstfyrslle dddmgdlvda 1021 eeylvpqqgf fcpdpapgag gmvhhhrhrss strnm (SEQ ID NO: 5, corresponds to receptor tyrosine-protein kinase erbB-2 isoform d precursor [Homo sapiens] and GenBank accession number NP_001276866).

[0406] The wild-type HER2 receptor sequence of the present disclosure may comprise or consist of the following amino acid sequence: 1 mklrlpaspe thldmlrhly qgcqvvqgnl eltylptnas lsflqdiqev qgyvliahnq 61 vrqvplqrlr ivrgtqlfed nyalavldng dplnnttpvt gaspgglrel qlrslteilk 121 ggvliqrnpq lcyqdtilwk difhknnqla ltlidtnrsr achpcspmck gsrcwgesse 181 dcqsltrttvc aggcarckgp lptdccheqc aagctgpkhs dclaclhfnh sgicelhcpa 241 lvtyntdtfe smpnpegryt fgascvtacp ynylstdvgs ctlvcplhnq evtaedgtqr 301 cekcskpcar vcyglgmehl revravtsan iqefagckki fgslaflpes fdgdpasnta 361 plqpeqlqvf etleeitgyl yisawpdslp dlsvfqnlqv irgrilhnga ysltlqglgi 421 swlglrslre lgsglalihh nthlcfvhtv pwdqlfrnph qallhtanrp edecvgegla 481 chqlcarghc wgpgptqcvn csqflrgqec veecrvlqgl preyvnarhc lpchpecqpq 541 ngsvtcfgpe adqcvacahy kdppfcvarc psgvkpdlsy mpiwkfpdee gacqpcpinc 601 ths (SEQ ID NO: 6, corresponds to receptor tyrosine-protein kinase erbB-2 isoform e [Homo sapiens] and GenBank accession number NP_001276867).

[0407] Based on the definitions provided throughout this application, one of ordinary skill in the art will know which combinations are synthetically feasible and practical, e.g., typical combinations of groups resulting in heteroatoms directly linked to each other are not contemplated.

[0408] As used herein, the term "about" refers to a range that encompasses any normal variation recognized by those skilled in the art. In some embodiments, the term "about" refers to a range of values that falls within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less in either direction (higher or lower) of the stated reference value, unless otherwise stated or otherwise clear from the context (except where the numerical value in question may exceed 100%).

[0409] As used herein, the term "pharmaceutically acceptable salts" refers to derivatives of the compounds of the present disclosure in which the parent compound has been modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, etc. Pharmaceutically acceptable salts include the conventional non-toxic salts or quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such common non-toxic salts include, but are not limited to, 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, 1,2-ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, glycolylarsanilic acid, hexylresorcylic acid, hydrabamic acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, hydroxymaleic acid, hydroxynaphthoic acid, isethionic acid, lactic acid, and lactobion. Included are salts obtained from inorganic and organic acids selected from laurylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, napsylic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, subacetic acid, succinic acid, sulfamic acid, sulfanilic acid, sulfuric acid, tannic acid, tartaric acid, toluenesulfonic acid, and commonly occurring amino acids such as glycine, alanine, phenylalanine, arginine, etc. Other examples of pharmaceutically acceptable salts include hexanoic acid, cyclopentanepropionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-ene-1-carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, and muconic acid.The present disclosure also encompasses salts formed when an acidic proton contained in a parent compound is replaced with a metal ion, such as an alkali metal ion, alkaline earth ion, or aluminum ion, or coordinated with an organic base, such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. In the salt form, it is understood that the ratio of the compound to the cation or anion of the salt can be 1:1, or any ratio other than 1:1, such as 3:1, 2:1, 1:2, or 1:3. It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystalline forms (polymorphs), as defined herein, of the same salt.

[0410] It is understood that the compounds described herein include, where applicable, the compounds themselves, as well as their pharmaceutically acceptable salts and their solvates.Pharmaceutically acceptable salts can be formed, for example, between a pharmaceutically acceptable anion on the compound and a positively charged group (e.g., amino).Suitable anions include chloride, bromide, iodide, sulfate, bisulfate, sulfamic acid, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamic acid, glucuronate, glutaric acid, malic acid, maleic acid, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate and acetate (e.g., trifluoroacetate).

[0411] It is understood that the compounds of the present disclosure, for example, the salts of compounds, can exist in either hydrated form or non-hydrated (anhydrous) form, or as solvates with other solvent molecules.Non-limiting examples of hydrates include monohydrates and dihydrates.Non-limiting examples of solvates include ethanol solvates and acetone solvates.

[0412] As used herein, unless otherwise indicated, the expressions "one or more of A, B, or C," "one or more of A, B, or C," "one or more of A, B, and C," "one or more of A, B, and C," "selected from the group consisting of A, B, and C," "selected from A, B, or C," and the like are used interchangeably and all refer to a selection from the group consisting of A, B, and / or C, i.e., one or more A, one or more B, one or more C, or combinations thereof.

[0413] It should be understood that throughout the description, compositions may be described as having, including, or comprising particular components, and it is contemplated that the compositions also consist essentially of or consist of the recited components. Similarly, when a method or process is described as having, including, or comprising particular process steps, the process also consists essentially of or consists of the recited process steps. Furthermore, it should be understood that the order of steps, or sequence for performing particular actions, is immaterial so long as the invention remains operable. Moreover, two or more steps or actions may be performed simultaneously.

[0414] It will be understood that the compounds of the present disclosure can be made in a variety of ways using commercially available starting materials, compounds known in the literature, or readily made intermediates by employing standard synthetic methods and procedures that are known to those of skill in the art or that will be apparent to those skilled in the art in light of the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. See, for example, but not limited to, any one or more sources, Smith, MB, March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5 thedition,John Wiley & Sons:New York,2001;Greene,TW,Wuts,PGM,Protective Groups in Organic Synthesis,3 rd edition, John Wiley & Sons: New York, 1999; R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), are useful and widely recognized references on organic synthesis known to those skilled in the art and are incorporated herein by reference.

[0415] As used herein, the term "subject" includes human and non-human mammals, as well as cell lines, cell cultures, tissues, and organs. In some embodiments, the subject is a mammal. The mammal may be, for example, a human or a suitable non-human mammal, such as a primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep, or pig. The subject may also be a bird or poultry. In some embodiments, the subject is a human.

[0416] As used herein, the term "subject in need thereof" refers to a subject who has a disease (to be treated) or is at high risk of developing a disease (to be prevented). A subject in need thereof may have previously been diagnosed or identified as having a disease or disorder disclosed herein. A subject in need thereof may also have (e.g., suffer from) a disease or disorder disclosed herein. Alternatively, a subject in need thereof can be at high risk for developing such a disease or disorder compared to the population as a whole (i.e., a subject who is more prone to developing such a disorder compared to the population as a whole). A subject in need thereof can have a disease or disorder disclosed herein that is refractory or resistant (i.e., a disease or disorder disclosed herein that does not respond or has not yet responded to treatment). A subject may be resistant at the start of treatment or may become resistant during treatment. In some embodiments, a subject in need thereof has undergone and failed all known effective therapies for a disease or disorder disclosed herein. In some embodiments, a subject in need thereof has undergone at least one prior therapy.

[0417] As used herein, the term "treating" or "treat" refers to the management and care of a patient for the purpose of combating a disease, condition, or disorder, and includes the administration of a compound of the present disclosure, or a pharmaceutically acceptable salt, polymorph, or solvate thereof, to alleviate the symptoms or complications of the disease, condition, or disorder, or to eliminate the disease, condition, or disorder. The term "treat" can also include the treatment of a cell in vitro or in an animal model.

[0418] It will be understood that the compounds of the present disclosure, or pharmaceutically acceptable salts, polymorphs or solvates thereof, may prevent or may be used to prevent the associated disease, condition, or disorder, or may be used to identify suitable candidates for such purposes.

[0419] As used herein, the terms "preventing," "prevent," or "protect from" refer to reducing or eliminating the onset of symptoms or complications of such diseases, conditions, or disorders.

[0420] As used herein, the term "temporal proximity" refers to the administration of one therapeutic agent (e.g., Compound 2 (e.g., Compound 2A or Compound 2B)) within a period of time before or after the administration of another therapeutic agent (e.g., temozolomide) such that the therapeutic effect of one therapeutic agent overlaps with the therapeutic effect of the other therapeutic agent. In some embodiments, the therapeutic effect of one therapeutic agent completely overlaps with the therapeutic effect of the other therapeutic agent. In some embodiments, "temporal proximity" refers to the administration of one therapeutic agent within a period of time before or after the administration of another therapeutic agent such that there is a synergistic effect between one therapeutic agent and the other therapeutic agent. "Temporal proximity" can vary depending on various factors, including, but not limited to, the age, sex, weight, genetic background, medical condition, disease and treatment history of the subject to whom the therapeutic agent is administered, the disease or condition to be treated or ameliorated, the therapeutic result to be achieved, the dose, frequency of administration, duration of administration of the therapeutic agent, the pharmacokinetics and pharmacodynamics of the therapeutic agent, and the route by which the therapeutic agent is administered. In some embodiments, "proximity in time" means within 15 minutes, within 30 minutes, within 1 hour, within 2 hours, within 4 hours, within 6 hours, within 8 hours, within 12 hours, within 18 hours, or within 24 hours. In some embodiments, multiple administrations of one therapeutic agent may be administered in close temporal proximity to a single administration of another therapeutic agent. In some embodiments, the proximity in time may vary during a treatment cycle or within a dosing regimen.

[0421] As used herein, the term "pharmaceutically acceptable" means compounds, anions, cations, substances, compositions, carriers, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0422] As used herein, the term "pharmaceutically effective amount" refers to an amount of a pharmaceutical agent that treats, ameliorates, or prevents an identified disease or condition, or that exhibits a detectable therapeutic or suppressive effect. The effect can be detected by any assay method known in the art. The exact effective amount for a subject will depend on the subject's weight, size, and health; the nature and extent of the condition; and the therapeutic agent or combination of therapeutic agents selected for administration. The pharmaceutically effective amount for a given situation can be calculated by routine experimentation, which is within the skill and judgment of the clinician.

[0423] For compounds of the present disclosure that are capable of further forming salts, it is understood that all of these forms are also contemplated within the scope of the claimed disclosure.

[0424] As used herein, the term "pharmaceutically acceptable salt" refers to a derivative of a compound of the present disclosure, in which the parent compound is modified by making an acid salt or base salt thereof. In some embodiments, a pharmaceutically acceptable salt of a compound is also a prodrug of the compound. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like. Pharmaceutically acceptable salts include the conventional non-toxic salts or quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such common non-toxic salts include, but are not limited to, 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, 1,2-ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, glycolylarsanilic acid, hexylresorcylic acid, hydrabamic acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, hydroxymaleic acid, hydroxynaphthoic acid, isethionic acid, lactic acid, and lactobion. Included are salts obtained from inorganic and organic acids selected from laurylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, napsylic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, subacetic acid, succinic acid, sulfamic acid, sulfanilic acid, sulfuric acid, tannic acid, tartaric acid, toluenesulfonic acid, and commonly occurring amino acids such as glycine, alanine, phenylalanine, arginine, etc.

[0425] Other examples of pharmaceutically acceptable salts include hexanoic acid, cyclopentanepropionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-ene-1-carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, and muconic acid, etc. The present disclosure also encompasses salts formed when an acidic proton in the parent compound is replaced with a metal ion, e.g., an alkali metal ion, alkaline earth ion, or aluminum ion, or coordinated with an organic base, e.g., ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, etc. It is understood that in the salt form, the ratio of the compound to the cation or anion of the salt can be 1:1, or any ratio other than 1:1, for example, 3:1, 2:1, 1:2, or 1:3.

[0426] It is understood that all references to pharmaceutically acceptable salts include the solvent addition forms (solvates) or crystal forms (polymorphs), as defined herein, of the same salt.

[0427] As used herein, the term "prodrug" refers to any agent that, when administered to a mammal, is converted, in whole or in part, into a target compound. In some embodiments, a prodrug of a compound is also a pharmaceutically acceptable salt of the compound.

[0428] It is understood that the compounds of the present disclosure can also be prepared as esters, for example, pharmaceutically acceptable esters. For example, the carboxylic acid functional group of the compound can be converted to its corresponding ester (e.g., methyl ester, ethyl ester, or other ester). Furthermore, the alcohol group of the compound can be converted to its corresponding ester (e.g., acetate ester, propionate ester, or other ester).

[0429] The compound, or its pharmaceutically acceptable salt, can be administered orally, intranasally, transdermally, pulmonary, inhalation, buccal, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally, and parenterally. In one embodiment, the compound is administered orally. Those skilled in the art will recognize the advantages of certain administration routes.

[0430] Dosage regimens using the present compounds are selected according to a variety of factors, including the type, species, age, weight, sex, and medical condition of the patient, the severity of the condition being treated, the route of administration, the renal and hepatic function of the patient, the particular compound or salt thereof being used, etc. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, retard, or arrest the progress of the condition.

[0431] Techniques for formulation and administration of the disclosed compounds of this disclosure are described in Remington: The Science and Practice of Pharmacy, 1999. th edition, Mack Publishing Co., Easton, PA (1995). In some embodiments, the compounds described herein and their pharmaceutically acceptable salts are used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents, and sterile aqueous or organic solutions. The compound will be included in such pharmaceutical compositions in an amount sufficient to provide the desired dosage within the range described herein.

[0432] Various in vitro or in vivo biological assays may be suitable for detecting the effects of the compounds of the present disclosure, including, but not limited to, enzyme activity assays, electrophoretic mobility shift assays, reporter gene assays, in vitro cell viability assays, and assays described herein.

[0433] All percentages and ratios used herein are by weight unless otherwise specified. Other features and advantages of the present disclosure will become apparent from the various examples. The examples provided illustrate various components and methods useful in practicing the present disclosure. The examples do not limit the claimed disclosure. Based on this disclosure, one skilled in the art will be able to identify and use other components and methods useful in practicing the present disclosure.

[0434] All publications and patent documents cited herein are incorporated by reference as if each individual publication or document was specifically and individually indicated to be incorporated by reference. Citation of publications and patent documents does not constitute an admission that any is pertinent prior art, nor any admission as to the contents or date. While the invention has been described by way of description, those skilled in the art will recognize that the invention may be practiced in various embodiments, and that the above description and the examples set forth below are intended to be illustrative and not limiting of the claims that follow. [Example]

[0435] Example 1. Selectivity of Compound 1A for allosteric EGFR variants expressed in GBM To evaluate the selectivity of compound 1A against EGFR allosteric mutants, antiproliferative IC 50 Values were determined for Compound 1A in EGFR-WT, EGFR-Viii, EGFR-Vii, EGFR-Vvi, EGFR-A289V, and EGFR-G598V. See, e.g., Figure 1.

[0436] Example 2. Plasma and brain concentrations of Compound 1A To assess the ability of Compound 1A to penetrate the brain, the mean plasma and brain concentrations of Compound 1A were determined when administered at 15 mg / kg. The unbound partition coefficient (K puu) was determined to be 0.19. See, e.g., Figure 2. Figure 10 shows the mean plasma concentrations of Compound 1A in mice when administered orally (PO) at 15 mg / kg and via IV bolus at 1 mg / kg. Pharmacokinetic (PK) parameters were measured for mice after oral administration (PO) of Compound 1A at 15 mg / kg and via IV bolus at 1 mg / kg, as shown in Table A below. [Table 8]

[0437] Example 3. Engagement of allosteric EGFR mutants with compound 1A in vivo The relationship between pEGFR and Compound 1A administration was determined in BaF3-EGFR V2 xenograft MI4029. See, e.g., Figure 3.

[0438] Example 4. Compound 1A inhibits tumor growth of intracranial PDX tumors expressing allosteric EGFR mutants To evaluate the ability of Compound 1A to inhibit tumor growth, the normalized bioluminescence intensity (BLI) of EGFR-VIII-expressing GBM6 orthotopic brain patient-derived xenograft tumors was determined when treated with 50 mg / kg, 15 mg / kg, or 5 mg / kg of Compound 1A (see, e.g., Figure 4).

[0439] Example 5. Selectivity of Compound 2B for allosteric EGFR variants expressed in GBM To evaluate the selectivity of compound 2B against EGFR allosteric mutants, antiproliferative IC 50 Values were determined for Compound 2B in EGFR-WT, EGFR-Viii, EGFR-Vii, EGFR-A289V, and EGFR-G598V. See, e.g., Figure 5.

[0440] Example 6. Plasma and brain concentrations of Compound 2B To evaluate the ability of Compound 2B to penetrate the brain, the mean plasma and brain concentrations of Compound 2B were determined when administered at 15 mg / kg. See, for example, Figure 6. Figure 11 shows the mean plasma concentrations of Compound 2B in mice administered orally (PO) at 15 mg / kg and via IV bolus at 1 mg / kg. Pharmacokinetic (PK) parameters were measured for mice administered Compound 2B orally (PO) at 15 mg / kg and via IV bolus at 1 mg / kg, as shown in Table B below. [Table 9]

[0441] Example 7. Engagement of allosteric EGFR mutants with compound 2B in vivo The relationship between pEGFR and Compound 2B administration was determined in BaF3-EGFR V3 xenograft MI4415. See, e.g., Figure 7.

[0442] Example 8. Compound 2B inhibits tumor growth of intracranial PDX tumors expressing allosteric EGFR mutants To evaluate the ability of Compound 2B to inhibit tumor growth, the normalized bioluminescence intensity (BLI) of EGFR-Viii-expressing GBM6 orthotopic brain patient-derived xenograft tumors was determined when treated with 150 mg / kg, 50 mg / kg, or 15 mg / kg of Compound 2B (see, e.g., Figure 8).

[0443] Example 9. Selectivity of osimertinib for allosteric EGFR variants expressed in GBM To evaluate the selectivity of osimertinib for EGFR allosteric mutants, we performed antiproliferative IC 50 Values were determined for osimertinib in EGFR-WT, EGFR-Viii, EGFR-Vii, EGFR-Vvi, and EGFR-A289V. See, for example, Figure 9. Potency and selectivity are not as pronounced with osimertinib compared to Compound 1A and Compound 2B.

[0444] Example 10. Compound 1A increases survival in mice developing intracranial GBM6 patient-derived tumors To evaluate the efficacy of Compound 1A, we determined the survival rate of mice bearing intracranial GBM6 patient-derived tumors when orally administered 50 mg / kg of Compound 1A. Figure 12 shows that survival increased over a longer treatment period.

[0445] Example 11. Compound 2B increases survival in mice developing intracranial GBM6 patient-derived tumors To evaluate the efficacy of Compound 2B, the survival rate of mice bearing intracranial GBM6 patient-derived tumors was determined when Compound 2B was orally administered at 50 mg / kg. Figure 13 shows that survival increased over a longer treatment period.

[0446] Example 12. Compound 2B shown to achieve potent and selective inhibition of a spectrum of allosteric EGFR variants To evaluate the efficacy of compound 2B for inhibiting allosteric EGFR variants expressed in GBM and / or NSCLC, antiproliferative IC 50 Compound 2B inhibited wild-type EGFR (H292), amplified wild-type EGFR (A431), EGFRvIII, EGFRvII, EGFRvV1, EGFR-R222C, EGFR-C231F, EGFR-A289V, EGFR-C595S, EGFR-G598V, EGFR-D761Y, EGFR-G719C, EGFR-G719D, EGFR-G719R, EGFR-E746-A750del, EGFR-L858R, EGFR-E746-A750del+C797, and EGFR-E746-A750del+C797S+T790M. See, e.g., Figure 14A. Compound 2B also exhibited an antiproliferative IC of less than 10 nM. 50Compound 2B was demonstrated to inhibit EGFR-R108K, EGFR-A298T, and EGFR-S645C. See, for example, Figure 14B. Compound 2B demonstrated low activity against wild-type EGFR (H292) and moderate activity against amplified wild-type EGFR (A431). Antiproliferative IC 50 Values were also determined for osimertinib. See, for example, Figure 14C. Compound 2B was found to have increased potency and selectivity against EGFR mutations occurring in GBM compared to osimertinib. Furthermore, compound 2B demonstrated activity against the C797S resistance mutation. Figures 22 and 23 also demonstrate greater than 10-fold selectivity against EGFR variants and mutations found in GBM, as well as intrinsic and acquired resistance in NSCLC.

[0447] Example 13. Compound 2B exhibits a favorable preclinical CNS PK profile across species PK parameters were measured for PO administration of Compound 2B in mice (15 mg / kg), rats (30 mg / kg), and dogs (30 mg / kg). See, e.g., Figures 15-17. The unbound partition coefficient (K) in mouse brain was puu ) was determined to be 0.19. K for rats puu was determined to be 0.81 in the brain and 0.90 in the cerebrospinal fluid (CSF). puu was determined to be 0.22 in CSF.

[0448] Example 14. Clinical trial of compound 2B The study consists of modules evaluating compound 2B as a single agent or in combination with other therapies for the treatment of patients with GBM or NSCLC.

[0449] Each module consists of a dose escalation phase and a dose expansion phase. Patients will be enrolled in each module as follows: Module 1: GBM with relapsed / refractory (RR) after primary surgery or NSCLC with EGFR C797S or E18 mutations. Module 2: GBM in patients eligible for treatment with temozolomide (TMZ). Module 3: GBM or NSCLC with EGFR C797S or E18 mutations eligible for surgical resection.

[0450] NSCLC patients had their EGFR C797S or exon 18 mutation status documented by a validated NGS assay routinely used at each institution, and provided a baseline tumor sample for retrospective concordance testing with a companion diagnostic test.

[0451] Example 15. Irreversible Inhibition in Vitro with Compound 2B The irreversibility of compound 2B was determined in a washout study in Ba / F3 EGFRvIII. See, e.g., Figure 18.

[0452] The irreversibility of compound 2B against the C797S mutant was also determined, inhibiting pEGFR Ex19 / C797S for >24 hours at 34 nM, while osimertinib at 1,000 nM shows complete washout after 0.5 hours. See, e.g., Figure 24.

[0453] Example 16. Irreversible Inhibition in Vivo with Compound 1 Relationship between administration of pEGFR(P1068) and Compound 1 in mice bearing BaF3 allograft tumors expressing EGFR-Viii. See, e.g., Figure 19A.

[0454] Example 17. Irreversible Inhibition in Vivo with Compound 1A Relationship between administration of pEGFR(P1068) and Compound 1A in mice bearing BaF3 allograft tumors expressing EGFR-Viii. See, e.g., Figure 19B.

[0455] Example 18. Irreversible Inhibition in Vivo with Compound 2B Relationship between administration of pEGFR(P1068) and Compound 2B in mice bearing BaF3 allograft tumors expressing EGFR-Viii. See, e.g., Figure 19C.

[0456] Example 19. In vivo tumor growth inhibition using compound 2B Median tumor volume (mm 3 The relationship between mean tumor volume (mm ) and administration of Compound 2B was determined in a subcutaneous GBM46 PDX-expressing EGFRvII mouse model. See, e.g., Figure 20. 3 The relationship between EGFR exon 19 deletion and administration of Compound 2B was determined in the Ba / F3-EGFR exon 19 deletion+C797S mouse allograft model when Compound 2B was administered at 40 mg / kg or 120 mg / kg. See, e.g., Figures 25 and 26.

[0457] Example 20. Compound 2B inhibits EGFR Ex19del and Ex19del / C797S-driven cell lines The ability of compound 2B to selectively bind EGFR Ex19del and Ex19del / C797S-driven cell lines without sacrificing selectivity for EGFR WT is shown in Table C below. Compound 2B is an irreversible EGFR inhibitor that is selective for EGFR Ex19del and Ex19del / C797S over EGFR WT. The data shown in Table C are approximate and subject to experimental and machine variations. [Table 10]

[0458] Example 21. Body weight is not affected by Compound 2B The relationship between % body weight and administration of Compound 2B was determined in a subcutaneous GBM46 PDX-expressing EGFRvII mouse model. See, e.g., Figure 21.

[0459] Dose escalation Within each module, patients are first enrolled in a dose escalation phase.

[0460] All modules will use a Bayesian optimal interval (BOIN) dose escalation design with dose levels of 400 mg, 600 mg, 800 mg, and 1000 mg QD (n=7 for each dose level).

[0461] In Module 1 only, dose escalation of Compound 2B will begin initially as an accelerated escalation of 25 mg, 50 mg, and 100 mg QD (n=1 for each dose). Potential doses will be explored using a BOIN design and include dose levels of 200 mg, 400 mg, 600 mg, and 800 mg QD, and 200 mg, 300 mg, 400 mg, and 500 mg BID.

[0462] Additionally, 12 patients in Module 1 will participate in a food or enzyme-inducing antiepileptic drug (EIAD) drug-drug interaction (DDI) evaluation (n=12 per treatment) using either the 400 mg or 600 mg QD dosing regimen.

[0463] Selected GBM patients will be enrolled in Module 1 to evaluate the pharmacodynamic effects of compound 2B in a backfilled pharmacodynamic (PDc) cohort (n=3).

[0464] For modules 2 and 3, three dose levels may be explored, the first being one dose level below the RP2D determined in module 1.

[0465] The primary objective of the dose escalation phase of each module is to identify the MTD of compound 2B as monotherapy or combination therapy and determine the RP2D as monotherapy or combination therapy. The safety and PK profile of compound 2B will be reviewed to determine whether the dose expansion phase of the module should be initiated and, if so, to recommend the MTD.

[0466] Dose expansion The dose expansion phase will evaluate the antitumor efficacy of compound 2B monotherapy or combination therapy at RP2D. The cohorts evaluated in each module are presented below.

[0467] Module 1: GBM patients with recurrent / refractory (RR) disease after initial tumor resection and NSCLC patients with EGFR C797S or exon 18 mutations for whom standard therapy is unavailable or inappropriate.

[0468] Module 2: GBM in patients eligible for treatment with temozolomide (TMZ).

[0469] Module 3: Newly diagnosed GBM (before initial tumor resection); and NSCLC with EGFR C797S or E18 mutations

[0470] Test treatment Compound 2B will be administered orally over a 21-day treatment cycle. Depending on the results of the food effect assessment portion of the dose escalation phase of Module 1, Compound 2B may be administered with food.

[0471] Study treatment will continue until disease progression (PD), unacceptable drug-related toxicity, death, initiation of new anticancer therapy, withdrawal of consent, or loss to follow-up. Study treatment will be discontinued 52 weeks after the last patient's first study visit unless the patient tolerates the study drug and derives clinical benefit. Study treatment will be discontinued in patients with confirmed PD or who have initiated subsequent anticancer therapy.

[0472] Patients who complete the first cycle of treatment without evidence of significant toxicity or clinical evidence of progressive disease may receive an additional 21-day treatment cycle at the same dose level.

[0473] Exam evaluation Patients are required to return during the treatment and post-treatment periods for collection of study assessments.

[0474] Tumor imaging will be performed every 6 weeks for the first 8 cycles and every 12 weeks thereafter to assess tumor response using RECIST 1.1 or RANO as appropriate.

[0475] Safety and tolerability will be assessed through reporting of adverse events (AEs), clinical laboratory tests, and electrocardiogram (ECG), echocardiogram (or MUGA), and physical examination findings. Dose-limiting toxicities will be assessed using the NCI CTCAE version 5.0.

[0476] Pharmacokinetic sampling will be collected on days 1 and 15 of cycle 1 and on day 1 of each subsequent cycle.

[0477] Exploratory biomarker assessments will be performed on plasma ctDNA samples collected after each treatment cycle, and in GBM patients, on CSF ctDNA collected at baseline and EOT.

[0478] Study drug / treatment group, dose, and administration method In each module, patients receive the following treatments: Module 1: Single Agent Compound 2B Module 2: Compound 2B in combination with temozolimide Module 3: Compound 2B as a monotherapy or combination therapy

[0479] Compound 2B is administered orally.

[0480] Treatment / Study Period: Each patient will continue study treatment until progressive disease (PD), death, or discontinuation, as determined by the patient or investigator. The expected treatment duration for each patient is 6 months.

[0481] The overall duration of the study is approximately four years.

[0482] Example 22. Clinical trial of compound 2B A phase 1, open-label, multicenter study of compound 2B was conducted in patients with recurrent GBM harboring EGFR alterations or locally advanced or metastatic NSCLC with specific EGFR mutations. The study schema is shown in Figure 27.

[0483] The monotherapy dose-escalation portion of this study will evaluate compound 2B in patients with either recurrent GBM-expressing EGFR alterations, with or without CNS disease, or advanced / metastatic NSCLC harboring a susceptible EGFR mutation. The Phase 1 study will also include a pilot food-effect cohort, as well as a leptomeningeal disease (LMD) cohort, to further evaluate CNS drug penetration and target-related alterations or ctDNA in the CSF of patients with leptomeningeal disease. Once a tentative RP2D is established based on safety, PK, PDx, and tolerability data, compound 2B monotherapy will be explored in specific disease settings, with further evaluation of safety, PK, and preliminary efficacy assessments. Disease-specific expansions include: 1) patents with GBM harboring EGFR mutations and other variants; and 2) patents with advanced / metastatic NSCLC harboring rare mutations such as G719S or acquired mutations such as C797S. Once the safety of monotherapy is established, compound 2B will be administered in combination with TMZ to evaluate the safety, tolerability, and recommended combination dose for the treatment of patients with recurrent GBM harboring EGFR mutations or variants.

[0484] Dose escalation of monotherapy The maximum tolerated dose (MTD) of compound 2B as monotherapy will be estimated using accelerated titration followed by a Bayesian optimal interval (BOIN) design. The starting dose is 15 mg orally once daily. Initial dose escalation is proposed as an accelerated titration in a single patient cohort at 15 mg, 25 mg, 50 mg, and 100 mg once daily (QD) to minimize the number of patients potentially at subtherapeutic dose levels.

[0485] A multi-patient dose cohort design will be initiated at 200 mg QD or earlier if Grade 2 or higher drug-related adverse events are observed. Further incremental doses will be explored using a BOIN design to identify the MTD. Predefined dose levels include 200 mg, 400 mg, 600 mg, and 800 mg QD. Further expansion of previously enrolled dose levels and evaluation of intermediate dose levels will be conducted to further evaluate the safety, PK, preliminary efficacy, and PDx activity of compound 2B.

[0486] Leptomeningeal disease (LMD) cohort The LMD cohort will allow patients with leptomeningeal disease to receive Compound 2B treatment at dose levels identified as acceptable in monotherapy dose escalation (in patients without LMD). CSF sampling will be utilized to track CSF malignant cell counts in LMD patients, allowing for evaluation of investigational drug PK in the CSF, as well as target-specific changes in malignant cells or ctDNA. The LMD cohort will be open to enrollment only after monotherapy multiple patient dose levels are deemed acceptable by the SRC. LMD patients will receive Compound 2B daily and undergo evaluation in monotherapy dose escalation.

[0487] Pilot Food Effect (FE) Cohort A pilot FE cohort will be evaluated to obtain preliminary information regarding the effect of food on the PK of Compound 2B. Patients will be dosed in the fed / fasted state. PK will be obtained at 200 mg QD or at different doses based on emerging PK and safety data. Dose levels will not be tested in the FE cohort unless at least one dose level above it is deemed acceptable in the monotherapy dose expansion cohort. If data from the high-fat FE indicate so, the effect of a low-fat meal on the PK of Compound 2B will be evaluated as part of this cohort. Dose expansion cohort Once the RP2D is tentatively established in monotherapy dose escalation, confirmation of the RP2D and preliminary efficacy assessment will then be performed in disease-specific expansion cohorts. Dose expansion will enroll patients in the following disease-specific cohorts: Recurrent GBM with confirmed EGFR alterations Locally advanced or metastatic NSCLC with an acquired resistance EGFR mutation (C797S) after third-generation EGFR inhibitors (e.g., osimertinib) in the first-line setting and platinum-standard therapy, with or without CNS metastases. Locally advanced or metastatic NSCLC with oncogenic rare EGFR mutations (G719A / C / D / R / S, S768I, V769L, E709G / A, D716Y, or other mutations validated by the sponsor) that have progressed after EGFR inhibitor and platinum-based standard therapy, with or without CNS metastases.

[0488] A single RP2D is expected from dose escalation across both GBM and NSCLC. However, if new data suggest disease-specific dose escalation, further dose adjustments will be made within specific patient groups. The RP2D, whether global or disease-specific as needed, will be selected based on overall safety and tolerability, PK, PDx, and preliminary antitumor activity.

[0489] Temozolomide (TMZ) combination A dose-finding evaluation will be performed using Compound 2B in combination with TMZ in patients with recurrent GBM harboring EGFR alterations. The initial dose of Compound 2B will begin at least one dose level lower than the preliminary RP2D identified during monotherapy dose escalation. The maximum dose of Compound 2B in combination with TMZ will not exceed the MTD of monotherapy. TMZ will be administered in this setting per standard of care: 150 mg / m on days 1-5 of each cycle (28 days). 2 P.O.

[0490] Recommendations for dose escalation or dose de-escalation of compound 2B are based on DLTs observed during cycle 1 of the combination using a BOIN design and will address the overall safety, tolerability, and available PK of the combination. The combination MTD will be defined as the dose level at which at least nine patients are enrolled, and de-escalation is not recommended as a next step.

[0491] Test treatment Compound 2B will be administered orally daily as monotherapy for 21-day treatment cycles or in combination with TMZ for 28-day treatment cycles. Study treatment will continue until disease progression (PD), unacceptable drug-related toxicity, death, initiation of new anticancer therapy, withdrawal of consent, or loss to follow-up.

[0492] Exam evaluation Tumor imaging will be collected. Tumor response will be assessed using RECIST 1.1 or RANO, as appropriate. Safety and tolerability will be assessed through reporting of adverse events (AEs), clinical laboratory tests, electrocardiograms (ECGs), echocardiograms (or MUGAs), and physical examination findings. Pharmacokinetic sampling will be collected and evaluated during treatment cycles. Exploratory biomarker assessments will be performed on plasma ctDNA, CTCs, and serum samples collected during each treatment cycle. In patients with CNS disease, assessments will be performed on collected CSF.

[0493] Study drug / treatment group, dose, and administration method Patients receive Compound 2B orally daily, either as a single agent or in combination with orally administered TMZ.

[0494] Doses will be assessed during the dose escalation portion, including: Compound 2B as a single agent: 15, 25, 50, 100, 200, 400, 600, and 800 mg QD administered in the fasted state. Intermediate dose levels will be evaluated based on safety and PK. For food effect evaluation, Compound 2B will be administered at least one dose level lower than that deemed acceptable as monotherapy and in the fasted or fed state (low-fat or high-fat meal). The pre-specified nominal dose for the food effect cohort will be 200 mg or 400 mg of Compound 2B, depending on emerging safety and PK data. For Compound 2B in combination with TMZ, the initial dose of Compound 2B in combination with TMZ will begin at least one dose level below the preliminary RP2D identified during monotherapy dose escalation. The maximum dose of Compound 2B in combination with TMZ will not exceed the MTD of monotherapy. TMZ will be administered in this setting per standard of care: 150 mg / m on days 1-5 of each 28-day cycle. 2 P.O.

[0495] The interim RP2D dose identified from the dose escalation portion of the study will be used in the dose expansion cohorts.

[0496] equivalent The details of one or more embodiments of the present disclosure are set forth in the accompanying description above. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, the preferred methods and materials are described herein. Other features, objects, and advantages of the present disclosure will be apparent from the description and claims. In this specification and the appended claims, the singular forms include plural referents unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents and publications cited herein are incorporated by reference. The foregoing description is presented for illustrative purposes only and is not intended to limit the disclosure to the precise form disclosed, other than as defined by the appended claims.

Claims

1. Compound 2 for treating or preventing cancer in a subject: or a pharma- ceutically acceptable salt thereof.

2. 2. The compound of claim 1, wherein the cancer is glioblastoma (GBM) or any subtype thereof.

3. The compound according to claim 1 or 2, wherein the cancer is glioblastoma.

4. The compound according to any one of claims 1 to 3, wherein the cancer is recurrent glioblastoma.

5. The compound according to any one of claims 1 to 4, wherein the cancer is non-small cell lung cancer (NSCLC) or any subtype thereof.

6. The compound according to any one of claims 1 to 5, wherein the cancer is non-small cell lung cancer (NSCLC).

7. The compound according to any one of claims 1 to 6, wherein the cancer is advanced or metastatic NSCLC.

8. The compound of any one of claims 1 to 7, wherein the cancer is NSCLC and the cancer has metastasized to the cerebrospinal fluid (CSF).

9. The compound of any one of claims 1 to 8, wherein the cancer is NSCLC and the cancer has metastasized to the brain.

10. The compound of any one of claims 1 to 9, wherein compound 2A, or a pharma- ceutically acceptable salt thereof, is administered.

11. The compound of any one of claims 1 to 10, wherein compound 2B, or a pharma- ceutically acceptable salt thereof, is administered.

12. The compound according to any one of claims 1 to 11, wherein the subject is a human.

13. Compound 2, or a pharma- ceutically acceptable salt thereof, about 15±10 mg, about 15±5 mg, about 15±4 mg, about 15±3 mg, about 15±2 mg, or about 15±1 mg, about 25±10 mg, about 25±5 mg, about 25±4 mg, about 25±3 mg, about 25±2 mg, or about 25±1 mg, about 50±10 mg, about 50±5 mg, about 50±4 mg, about 50±3 mg, about 50±2 mg, or about 50±1 mg, about 100±20 mg, about 100±10 mg, about 100±5 mg, about 100±4 mg, about 100±3 mg, about 100±2 mg, or about 100±1 mg, about 150±20 mg, about 150±10 mg, about 150±5 mg, about 150±4 mg, about 150±3 mg, about 150±2 mg, or about 150±1 mg, about 200±20 mg, about 200±10 mg, about 200±5 mg, about 200±4 mg, about 200±3 mg, about 200±2 mg, or about 200±1 mg, about 300±20 mg, about 300±10 mg, about 300±5 mg, about 300±4 mg, about 300±3 mg, about 300±2 mg, or about 300±1 mg, about 400±50 mg, about 400±40 mg, about 400±30 mg, about 400±20 mg, about 400±10 mg, about 400±5 mg, about 400±4 mg, about 400±3 mg, about 400±2 mg, or about 400±1 mg, about 500±50 mg, about 500±40 mg, about 500±30 mg, about 500±20 mg, about 500±10 mg, about 500±5 mg, about 500±4 mg, about 500±3 mg, about 500±2 mg, or about 500±1 mg, about 600±50 mg, about 600±40 mg, about 600±30 mg, about 600±20 mg, about 600±10 mg, about 600±5 mg, about 600±4 mg, about 600±3 mg, about 600±2 mg, or about 600±1 mg, about 800±50 mg, about 800±40 mg, about 800±30 mg, about 800±20 mg, about 800±10 mg, about 800±5 mg, about 800±4 mg, about 800±3 mg, about 800±2 mg, or about 800±1 mg, or 13. The compound of any one of claims 1 to 12, administered in a daily dose of about 1000±50 mg, about 1000±40 mg, about 1000±30 mg, about 1000±20 mg, about 1000±10 mg, about 1000±5 mg, about 1000±4 mg, about 1000±3 mg, about 1000±2 mg, or about 1000±1 mg.

14. The compound of any one of claims 1 to 13, wherein compound 2, or a pharma- ceutically acceptable salt thereof, is administered at a daily dose of about 15 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 800 mg, or about 1000 mg.

15. The compound of any one of claims 1 to 14, wherein the compound is administered in combination with a therapeutically effective amount of temozolomide.